View Filing Data

Document and Entity Information - USD ($)	12 Months Ended
Dec. 31, 2016	Feb. 14, 2017	Jun. 30, 2016
Document and Entity Information
Entity Registrant Name	Jaguar Animal Health, Inc.
Entity Central Index Key	0001585608
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 11,289,717
Entity Common Stock, Shares Outstanding		14,007,132
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	FY

Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 950,979	$ 7,697,531
Restricted cash	511,293
Accounts receivable	4,963	55,867
Due from former parent	299,648	3,199
Inventory	412,754	229,871
Deferred offering costs	72,710	143,231
Prepaid expenses	302,694	324,083
Total current assets	2,555,041	8,453,782
Property and equipment, net	885,945	829,232
Restricted cash		3,000,000
Other assets	122,163	122,163
Total assets	3,563,149	12,405,177
Current liabilities:
Accounts payable	517,000	574,462
License fee payable to former parent		425,000
Deferred revenue	224,454	251,936
Convertible notes payable	150,000	150,000
Accrued expenses	582,522	798,434
Warrant liability	799,201	0
Current portion of long-term debt	1,919,675	1,707,899
Total current liabilities	4,192,852	3,907,731
Long-term debt, net of discount	1,817,526	4,095,028
Deferred rent	6,956	3,321
Total liabilities	6,017,334	8,006,080
Commitments and Contingencies (See note 6)
Stockholders' Equity (Deficit):
Preferred stock: $0.0001 par value, 10,000,000 shares authorized at December 31, 2016 and December 31, 2015; no shares issued and outstanding at December 31, 2016 and December 31, 2015.
Common stock: $0.0001 par value, 50,000,000 shares authorized at December 31, 2016 and December 31, 2015; 14,007,132 and 8,124,923 shares issued and outstanding at December 31, 2016 and December 31, 2015, respectively.	1,401	812
Additional paid-in capital	37,980,522	30,100,613
Accumulated deficit	(40,436,108)	(25,702,328)
Total stockholders' equity	(2,454,185)	4,399,097
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$ 3,563,149	$ 12,405,177

Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue
Revenue	$ 141,523	$ 258,381
Operating Expenses
Cost of revenue	51,966	123,457
Research and development expense	7,206,864	6,475,851
Sales and marketing expense	485,440	765,091
General and administrative expense	5,983,238	5,339,351
Total operating expenses	13,727,508	12,703,750
Loss from operations	(13,585,985)	(12,445,369)
Interest expense, net	(985,549)	(3,317,287)
Other income/(expense)	(11,046)	(27,277)
Change in fair value of warrants	(43,200)	(501,617)
Loss on extinguishment of debt	(108,000)
Net loss and comprehensive loss	(14,733,780)	(16,291,550)
Accretion of redeemable convertible preferred stock		(346,374)
Net loss attributable to common stockholders	$ (14,733,780)	$ (16,637,924)
Net loss per share attributable to common stockholders, basic and diluted (in dollars per share)	$ (1.35)	$ (2.70)
Weighted-average common shares outstanding, basic and diluted (in shares)	10,951,178	6,153,139

Statement of Changes in Common Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)	Secondary public offering Common Stock	Secondary public offering Additional paid-in capital	Secondary public offering	Private Investment in Public Entities June 2016 Common Stock	Private Investment in Public Entities June 2016 Additional paid-in capital	Private Investment in Public Entities June 2016	Private Investment in Public Entities October 2016 Common Stock	Private Investment in Public Entities October 2016 Additional paid-in capital	Private Investment in Public Entities October 2016	Private Investment in Public Entities November 2016 Common Stock	Private Investment in Public Entities November 2016 Additional paid-in capital	Private Investment in Public Entities November 2016	Common Stock	Additional paid-in capital	Accumulated deficit	Series A redeemable convertible preferred stock	Total
Balance at Dec. 31, 2014													$ 288	$ 1,175,242	$ (9,410,778)	$ 7,304,914	$ (8,235,248)
Balance (in shares) at Dec. 31, 2014													2,874,330			3,015,902
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400													$ 286	15,511,974			15,512,260
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares)													2,860,000
Warrant, issued in conjunction with the initial public offering													$ 400,400	400,400			400,400
Conversion of preferred stock into common stock upon initial public offering													$ 201	7,651,087		$ (7,651,288)	7,651,288
Conversion of preferred stock into common stock upon initial public offering (in shares)													2,010,596			(3,015,902)
Conversion of preferred stock warrant liability into additional paid-in capital upon initial public offering														1,150,985			1,150,985
Conversion of convertible notes into common stock upon initial public offering													$ 37	2,099,963			2,100,000
Conversion of convertible notes to common stock upon initial public offering (in shares)													374,997
Stock-based compensation														992,165			992,165
Beneficial conversion feature on notes payable														1,202,521			1,202,521
Deemed dividends on Series A														(263,060)		$ 263,060	(263,060)
Accretion of issuance costs														(83,314)		83,314	(83,314)
Napo license fee abatement														250,000			250,000
Issuance of common stock upon exercise of stock options														12,650			12,650
Issuance of common stock upon exercise of stock options (in shares)													5,000
Net and comprehensive loss															(16,291,550)		(16,291,550)
Balance at Dec. 31, 2015													$ 812	30,100,613	(25,702,328)	$ 0	4,399,097
Balance (in shares) at Dec. 31, 2015													8,124,923
Increase (decrease) in Stockholders' Equity (Deficit)
Issuance of common stock in a secondary public offering ,net of discounts and commissions of $373,011 and offering costs of $496,887 February 2016	$ 200	$ 4,129,902	$ 4,130,102
Issuance of common stock in a secondary public offering ,net of discounts and commissions of $373,011 and offering costs of $496,887 February 2016 (in shares)	2,000,000
Issuance of common stock in a private investment in public entities offering, net of offering costs of $105,398 June 2016				$ 203	$ 2,571,099	$ 2,571,302
Issuance of common stock in a private investment in public entities offering, net of offering costs of $105,398 June 2016 (in shares)				2,027,490
Issuance of common stock in a private investment in public entities offering October 2016							$ 17	$ 149,983	$ 150,000
Issuance of common stock in a private investment in public entities offering October 2016 (in shares)							170,455
Issuance of common stock and equity warrants in a private investment in public entities offering, net of warrant liability of $700,001 and net of offering costs of $96,833 November 2016										$ 167	$ 203,000	$ 203,167
Shares issued (in shares)										1,666,668
Warrants, issued in conjunction with debt extinguishment														108,000			108,000
Stock-based compensation														717,927			$ 717,927
Issuance of common stock upon exercise of stock options													$ 2	(2)
Issuance of common stock upon exercise of stock options (in shares)													17,596				0
Net and comprehensive loss															(14,733,780)		$ (14,733,780)
Balance at Dec. 31, 2016													$ 1,401	$ 37,980,522	$ (40,436,108)		$ (2,454,185)
Balance (in shares) at Dec. 31, 2016													14,007,132

Statements of Cash Flow - USD ($)	12 Months Ended
Statements of Cash Flow - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Cash Flows from Operating Activities
Net loss	$ (14,733,780)	$ (16,291,550)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	47,494	5,155
Gain/loss on disposal of fixed assets		34,549
Loss on extinguishment of debt	108,000
Materials cost in connection with license activity		6,287
Issuance costs in connection with warrants issued in the November 2016 private investment in public entity	39,200
Stock-based compensation	717,927	992,165
Amortization of debt issuance costs and debt discount	510,085	2,720,668
Change in fair value of warrants	43,200	501,617
Changes in assets and liabilities
Accounts receivable - trade	50,904	(55,867)
Inventory	(182,883)	(31,842)
Prepaid expenses	21,389	(299,913)
Deferred offering costs	(72,710)
Other long-term assets		(122,163)
Due from parent	(296,449)	(19,780)
Deferred revenue	(27,482)	228,134
Deferred rent	3,635	3,321
License fee payable	(425,000)	(1,200,000)
Accounts payable	(28,336)	(240,087)
Accrued expenses	(188,912)	(546,557)
Total cash used in operations	(14,413,718)	(14,315,863)
Cash Flows from Investing Activities
Purchase of equipment	(104,207)	(23,300)
Sale of equipment		20,600
Change in restricted cash	2,488,707	(3,000,000)
Total cash provided by (used in) investing activities	2,384,500	(3,002,700)
Cash Flows from Financing Activities
Proceeds from issuance of long-term debt		5,615,543
Repayment of long-term debt	(2,488,706)
Proceeds from issuance of redeemable convertible notes payable, net		1,250,000
Repayment of convertible notes payable		(100,000)
Repayment of notes payable		(1,000,000)
Proceeds from issuance of common stock in initial public offering, net of commissions and discounts		18,810,484
Deferred offering costs		(417,775)
Proceeds from issuance of common stock in follow-on secondary offering, net of commissions and discounts	5,000,000
Proceeds from the exercise of common stock options		12,650
Total Cash Provided by Financing Activities	5,282,666	24,170,902
Net increase in cash and cash equivalents	(6,746,552)	6,852,339
Cash and cash equivalents, beginning of period	7,697,531	845,192
Cash and cash equivalents, end of period	950,979	7,697,531
Supplemental Schedule of Non-Cash Financing and Investing Activities
Interest paid on long-term debt	478,665	173,250
Warrants issued in connection with convertible notes payable		47,479
Warrants issued in connection with notes payable	108,000
Warrant, issued in conjunction with the initial public offering		400,400
Warrants issued in connection with private investment in public entity	756,001
Accretion of redeemable convertible preferred stock		346,374
Abatement of license fee payable to Napo		250,000
Conversion of convertible preferred stock to common stock		7,651,288
Conversion of preferred stock warrant liability to common stock warrants		1,150,985
Conversion of convertible notes to common stock		$ 2,100,000
Secondary public offering
Cash Flows from Financing Activities
Deferred offering costs	(869,898)
Private Investment in Public Entities June 2016
Cash Flows from Financing Activities
Deferred offering costs	(105,444)
Proceeds from issuance of common stock in a private investment in public entities, net of commissions, discounts	2,676,746
Private Investment in Public Entities October 2016
Cash Flows from Financing Activities
Proceeds from issuance of common stock in a private investment in public entities, net of commissions, discounts	150,000
Private Investment in Public Entities November 2016
Cash Flows from Financing Activities
Deferred offering costs	(80,033)
Proceeds from issuance of common stock in a private investment in public entities, net of commissions, discounts	$ 1,000,001

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2016
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make judgments, assumptions and estimates that affect the amounts reported in its financial statements and the accompanying notes. The accounting policies that reflect the Company's more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are valuation of stock options; valuation of warrant liabilities; impairment of long lived assets; useful lives for depreciation; valuation adjustments for excess and obsolete inventory; deferred taxes and valuation allowances on deferred tax assets; and evaluation and measurement of contingencies. Those estimates could change, and as a result, actual results could differ materially from those estimates. Deferred Offering Costs Deferred offering costs are costs incurred in filings of registration statements with the Securities and Exchange Commission. These deferred offering costs are offset against proceeds received upon the closing of the offerings. Deferred costs of $143,231 as of December 31, 2015 include legal, accounting and filing fees associated with the follow-on registration offering as more fully described in Note 9. Deferred costs of $72,710 as of December 31, 2016 include legal, accounting and filing fees associated with the Company's registration of unissued shares in the CSPA. Concentration of Credit Risk and Cash and Cash Equivalents Cash is the financial instrument that potentially subjects the Company to a concentration of credit risk as cash is deposited with a bank and cash balances are generally in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits. The carrying value of cash approximates fair value at December 31, 2016 and 2015. Fair Values The Company's financial instruments include, cash and cash equivalents, accounts payable, accrued expenses, amounts due to Napo, the former parent, warrant liabilities, and debt. Cash is reported at fair value. The recorded carrying amount of accounts payable, accrued expenses and amounts due to Napo approximates their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for bank loans with similar terms and maturities. See Note 3 for the fair value measurements, and Note 7 for the fair value of the Company's warrant liabilities. Restricted Cash On August 18, 2015, the Company entered into a long-term loan and security agreement with a lender for up to $8.0 million, which provided for an initial loan commitment of $6.0 million. The loan agreement required the Company to maintain a base minimum cash balance of $4.5 million until the Company met certain milestones and/or when the Company begins making principal payments. On December 22, 2015, the Company achieved certain milestones and the base minimum cash balance was reduced to $3.0 million. Aggregate principal payments of $2.5 million further reduced the restricted cash balance to $511,294 as of December 31, 2016. Restricted cash has been classified within current assets as restrictions will be fully released on April 1, 2017. Inventories Inventories are stated at the lower of cost or market. The Company calculates inventory valuation adjustments when conditions indicate that the net realizable value is less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand or reduction in selling price. Inventory write-downs are measured as the difference between the cost of inventory and estimated net realizable value. There have been no write-downs to date. Property and Equipment Equipment is stated at cost, less accumulated depreciation. Equipment begins to be depreciated when it is placed into service. Depreciation is calculated using the straight-line method over the estimated useful lives of 3 to 10 years. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their estimated useful lives. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in income (loss) from operations. Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset's fair value. The Company has not recognized any impairment losses through December 31, 2016. Research and Development Expense Research and development expense consists of expenses incurred in performing research and development activities including related salaries, clinical trial and related drug and non-drug product costs, contract services and other outside service expenses. Research and development expense is charged to operating expense in the period incurred. Revenue Recognition Sales of Neonorm Calf and Foal to distributors are made under agreements that may provide distributor price adjustments and rights of return under certain circumstances. Until the Company develops sufficient sales history and pipeline visibility, revenue and costs of distributor sales will be deferred until products are sold by the distributor to the distributor's customers. Revenue recognition depends on notification either directly from the distributor that product has been sold to the distributor's customer, when the Company has access to the data. Deferred revenue on shipments to distributors reflect the estimated effects of distributor price adjustments, if any, and the estimated amount of gross margin expected to be realized when the distributor sells through product purchased from the Company. Company sales to distributors are invoiced and included in accounts receivable and deferred revenue upon shipment. Inventory is relieved and revenue recognized upon shipment by the distributor to their customer. The Company had Neonorm revenues of $141,523 and $258,381 for the years ended December 31, 2016, and 2015. Stock-Based Compensation The Company's 2013 Equity Incentive Plan and 2014 Stock Incentive Plan (see Note 10) provides for the grant of stock options, restricted stock and restricted stock unit awards. The Company measures stock awards granted to employees and directors at fair value on the date of grant and recognizes the corresponding compensation expense of the awards, net of estimated forfeitures, over the requisite service periods, which correspond to the vesting periods of the awards. The Company issues stock awards with only service-based vesting conditions, and records compensation expense for these awards using the straight-line method. The Company uses the grant date fair market value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company's common stock as of the last day of each reporting period. Classification of Securities The Company applies the principles of ASC 480-10 "Distinguishing Liabilities from Equity" and ASC 815-40 "Derivatives and Hedging—Contracts in Entity's Own Equity" to determine whether financial instruments such as warrants, contingently issuable shares and shares subject to repurchase should be classified as liabilities or equity and whether beneficial conversion features exist. Financial instruments such as warrants that are evaluated to be classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in other income/(expense). The fair value of warrants is estimated using the Black Scholes Merton model and requires the input of subjective assumptions including expected stock price volatility and expected life. Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company's tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties. Comprehensive Loss Comprehensive loss is defined as changes in stockholders' equity (deficit) exclusive of transactions with owners (such as capital contributions and distributions). For the years ended December 31, 2016 and 2015 there was no difference between net loss and comprehensive loss. Segment Data The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is an animal health company focused on developing and commercializing prescription and non-prescription products for companion and production animals. Basic and Diluted Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted-average number of common shares, including potential dilutive shares of common stock assuming the dilutive effect of potential dilutive securities. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, because their impact would be anti-dilutive to the calculation of net loss per common share. Diluted net loss per common share is the same as basic net loss per common share for the years ended December 31, 2016 and 2015. Recent Accounting Pronouncements In November 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-18, Statement of Cash Flows: Restricted Cash, or ASU 2016-18, that will require entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. ASU 2016-18 becomes effective for fiscal years beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. Any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period. The adoption of this standard is not expected to have an impact on the Company's financial position or results of operations. In August 2016, the FASB issued Accounting Standards Update, or ASU, No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses the following cash flow issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and are effective for all other entities for fiscal years beginning after December 15, 2018 and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of ASU No. 2016-15 on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee stock-based payment transactions. The areas for simplification in ASU No. 2016-09 include the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this ASU will be effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-09 on our consolidated financial statements. In March 2016 the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. T ASU 2016-07 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently evaluating the potential effects of the adoption of this update on its financial statements. In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), which provides guidance for accounting for leases. Under ASU 2016-02, the Company will be required to recognize the assets and liabilities for the rights and obligations created by leased assets. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740), which simplifies the presentation of deferred income taxes. Under ASU 2015-17, deferred tax assets and liabilities are required to be classified as noncurrent, eliminating the prior requirement to separate deferred tax assets and liabilities into current and noncurrent. The new guidance is effective for the Company beginning on January 1, 2017, with early adoption permitted. The standard may be adopted prospectively or retrospectively to all periods presented. The Company elected to early adopt the standard on a retrospective basis effective December 31, 2015, and all deferred tax assets and liabilities are classified as non-current on our balance sheet. Adoption had no effect on the Company's balance sheet for 2016 and 2015 as presented. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. ASU 2015-03 will be effective for the Company beginning in its first quarter of 2016, however early adoption is permitted for financial statements that have not been previously issued. The guidance is to be applied retrospectively to all periods presented. The Company adopted ASU 2015-03 on December 31, 2015. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements—Going Concern (Subtopic 205-40)—Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", which provides guidance regarding management's responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company implemented this guidance for the annual period beginning after December 15, 2016. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In June 2014, the FASB issued ASU No. 2014-12, "Compensation—Stock Compensation (Topic 718)", which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This guidance is effective for annual periods (and interim periods within those annual periods) beginning after December 15, 2015. The Company implemented this guidance for all interim and annual periods beginning after December 15, 2015. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers." The objective of ASU 2014-19 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual reporting periods beginning after December 15, 2018 and allows for prospective or retrospective application. The Company currently anticipates utilizing the full retrospective method of adoption allowed by the standard, in order to provide for comparative results in all periods presented, and plans to adopt the standard as of January 1, 2018. The Company is currently evaluating the new guidance, however it does not believe the impact will be significant.

Fair Value Measurements

12 Months Ended

Dec. 31, 2016

Fair Value Measurements

Fair Value Measurements

3. Fair Value Measurements

ASC 820 "Fair Value Measurements," defines fair value, establishes a framework for measuring fair value under generally accepted accounting principles and enhances disclosures about fair value measurements. Fair value is defined under ASC 820 as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value under ASC 820 must maximize the use of observable inputs and minimize the use of unobservable inputs. The standard describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:


	•	Level 1—Quoted prices in active markets for identical assets or liabilities;
	•	Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and
	•	Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The following table presents information about the Company's warrant liabilities that were measured at fair value on a recurring basis as of December 31, 2016 and 2015 and indicates the fair value hierarchy of the valuation:

	Level 1		Level 2		Level 3		Total
As of December 31, 2016 Warrant Liability	$	—	$	—	$	799,201	$	799,201

There were no warrant liabilities at December 31, 2015.

The change in the estimated fair value of level 3 liabilities is summarized below:

	Beginning Value of Level 3 Liability		Issuance of Common Stock Warrants		Change in Fair Value of Level 3 Liability		Conversion into Additional Paid-in Capital			Ending Fair Value of Level 3 Liability
For the year ended December 31, 2016	$	—	$	756,001	$	43,200	$	—		$	799,201


For the year ended December 31, 2015	$	601,889	$	47,479	$	501,617	$	(1,150,985	)	$	—

The warrants issued in 2016 were originally valued on November 29, 2016 using the Black-Scholes-Merton model with the following assumptions: stock price of $0.69, exercise price of $0.75, term of 5.5 years expiring May 2022, volatility of 71.92%, dividend yield of 0%, and risk-free interest rate of 1.87%. The warrants were revalued at December 31, 2016 using the Black-Scholes model with the following assumptions: stock price of $0.716, exercise price of $0.75, term of 5.41 years expiring May 2022, volatility of 73.62%, dividend yield of 0%, and risk-free interest rate of 2.0%.

The change in the fair value of the level 3 warrant liability is reflected in the statement of operations and comprehensive loss for the years ended December 31, 2016 and 2015.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Related Party Transactions

12 Months Ended

Dec. 31, 2016

Related Party Transactions

Related Party Transactions

4. Related Party Transactions

Due from former parent

The Company was a majority-owned subsidiary of Napo until May 18, 2015, the date of the Company's IPO. Additionally, Lisa A. Conte, Chief Executive Officer of the Company, is also the interim Chief Executive Officer of Napo Pharmaceuticals, Inc. The Company has total outstanding receivables (payables) from/to former parent ("Napo") at December 31, 2016 and December 31, 2015 as follows:

	December 31, 2016			December 31, 2015
Due from former parent	$	299,819		$	6,008
Royalty payable to former parent		(171	)		(2,809	)

Net receivable from former parent	$	299,648		$	3,199

	December 31, 2016		December 31, 2015
License fee payable to former parent		—		(425,000	)

Due from former parent

Employee leasing and overhead allocation

Effective July 1, 2016, Napo agreed to reimburse the Company for the use of the Company's employee's time and related expenses, including rent and a fixed overhead amount to cover office supplies and copier use. The total amount of such services was $627,529 for the six months ended December 31, 2016. Napo remitted $350,000 in fiscal year 2016 and the remaining balance of $277,529 is included in current assets in the Company's balance sheet.

Other transactions

In 2016, the Company made $22,290 in payments for consulting, travel and computer equipment on behalf of Napo. In 2015, the Company made $6,008 in net payments on behalf of Napo, including $15,000 in Napo legal services paid by the Company, net of $8,992 of Company consulting services paid by Napo.

The Company purchased from Napo $37,355 of clinical trial material of which $897 of unused material remains in prepaid expenses and other current assets on the Company's balance sheet, crofelemer API of $174,299 all of which was used and expensed in 2016, and $66,358 of crude plant latex in 2016 none of which has been used in operations and all of which is included in prepaid expenses and other current assets in the Company's balance sheet. All of these purchases were paid in 2016.

The Company sublet office space from Napo from March 1, 2014 through May 31, 2014. The Company paid Napo $33,897 for rent related to the office space, which was included in general and administrative expense in the Company's statements of operations and comprehensive loss in 2014.

Royalty payable to former parent and license fee payable to former parent and related agreement

On July 11, 2013, Jaguar entered into an option to license Napo's intellectual property and technology (the "Option Agreement"). Under the Option Agreement, upon the payment of $100,000 in July 2013, the Company obtained an option for a period of two years to execute an exclusive worldwide license to Napo's intellectual property and technology to use for the Company's animal health business. The option price was creditable against future license fees to be paid to Napo under the License Agreement (as defined below).

In January 2014, the Company exercised its option and entered into a license agreement (the "License Agreement") with Napo for an exclusive worldwide license to Napo's intellectual property and technology to permit the Company to develop, formulate, manufacture, market, use, offer for sale, sell, import, export, commercialize and distribute products for veterinary treatment uses and indications for all species of animals. The Company was originally obligated to pay a one-time non-refundable license fee of $2,000,000, less the option fee of $100,000. At the Company's option, the license fee could have been paid in common stock. In January 2015, the License Agreement was amended to decrease the one-time non-refundable license fee payable from $2,000,000 to $1,750,000 in exchange for acceleration of the payment of the fee. Given that Napo is a significant shareholder of the Company, the abatement of the license fee amount has been recorded as a capital contribution in the accompanying condensed financial statements. In the years ending December 31, 2016 and 2015, the Company made payments of $425,000 and $1.2 million, respectively.

Milestone payments aggregating $3,150,000 may also be due to Napo based on regulatory approvals of various veterinary products. In addition to the milestone payments, the Company will owe Napo an 8% royalty on annual net sales of products derived from the Croton lechleri tree, up to $30,000,000 and then, a royalty of 10% on annual net sales of $30,000,000 or more. Additionally, if any other products are developed, the Company will owe Napo a 2% royalty on annual net sales of pharmaceutical prescription products that are not derived from Croton lechleri and a 1% royalty on annual net sales of non-prescription products that are not derived from Croton lechleri. The royalty term expires at the longer of 10 years from the first sale of each individual product or when there is no longer a valid patent claim covering any of the products and a competitive product has entered the market. However, because an IPO of at least $10,000,000 was consummated prior to December 31, 2015, the royalty was reduced to 2% of annual net sales of its prescription products derived from Croton lechleri and 1% of net sales of its non-prescription products derived from Croton lechleri and no milestone payment will be due and no royalties will be owed on any additional products developed. The Company incurred $1,015 and $39,734 in royalties for the years ended December 31, 2016 and 2015, respectively, which are included in sales and marketing expense in the Company's statement of operations and comprehensive loss. The Company had unpaid royalties of $171 and $2,810 at December 31, 2016 and 2015, respectively, which are netted with other receivables due from the former parent and are included in current assets in the Company's balance sheet. The Company may, at its sole discretion, elect to remit any milestone payments and/or royalties in the form of the Company's common stock.

In addition to receiving a License Agreement to Napo's intellectual property and technology, the License also transferred to the Company certain materials and equipment. Raw materials of $1.2 million transferred from Napo were included in research and development expense on the statements of operations and comprehensive loss during the year ended December 31, 2014. Equipment of $811,087 related to the License is included in property and equipment on the Company's balance sheet at December 31, 2016 and 2015 at the cost paid by Napo, which approximates fair value.

The Company has agreed under the License Agreement to defend, indemnify and hold Napo, its affiliates, and the officers, directors, employees, consultants and contractors of Napo harmless from and against any losses, costs, damages, liabilities, fees and expenses arising out of any third-party claim related to the Company's gross negligence, breach of covenants or the manufacture, sale or use of the product or products.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References + Details

Balance Sheet Components

12 Months Ended

Dec. 31, 2016

Balance Sheet Components

Balance Sheet Components

5. Balance Sheet Components

Property and Equipment

Property and equipment at December 31, 2016 and 2015 consisted of the following:

	December 31, 2016			December 31, 2015
Lab equipment	$	811,087		$	811,087
Clinical equipment		64,870			23,300
Software		62,637			—

Total property and equipment at cost		938,594			834,387
Accumulated Depreciation		(52,649	)		(5,155	)

Property and Equipment, net	$	885,945		$	829,232

Depreciation and amortization expense was $47,494 and $5,155 in the years ended December 31, 2016 and 2015 and was recorded in the statements of operations and comprehensive loss as follows:

	Years Ended December 31,
	2016		2015
Depreciation—Lab Equipment—research and developoment expense	$	26,271	$	4,378
Depreciation—Clinical Equipment—research and development expense		10,203		777
Depreciation—Software—general and administrative expense		11,020		—

Total Depreciation Expense	$	47,494	$	5,155

Accrued Expenses

Accrued expenses at December 31, 2016 and 2015 consist of the following:

	December 31, 2016		December 31, 2015
Accrued compensation and related:
Accrued vacation	$	223,769		187,734
Accrued payroll		2,692		80,692
Accrued payroll tax		20,140		43,702

		246,601		312,128
Accrued interest		123,982		127,149
Accrued contract manufacturing costs		—		110,141
Accrued clinical		36,725		166,750
Accrued other		175,214		82,266

Total	$	582,522		798,434

Debt and Warrants

12 Months Ended

Dec. 31, 2016

Debt and Warrants

Debt and Warrants

7. Debt and Warrants

Convertible Notes and Warrants

2013 Convertible Notes

From July through September 2013, the Company issued four convertible promissory notes (collectively the "Notes") for gross aggregate proceeds of $525,000 to various third-party lenders. The Notes bore interest at 8% per annum. The Notes automatically matured and the entire outstanding principal amount, together with accrued interest, was due and payable in cash at the earlier of July 8, 2015 (the "Maturity Date") or ten business days after the date of consummation of the initial closing of a first equity round of financing. The Company consummated a first equity round of financing prior to the Maturity Date with a pre-money valuation of greater than $3.0 million, and, accordingly, principal and accrued interest was converted into shares of common stock at 75% of the purchase price paid by such equity investors. These notes were all converted to common stock in February 2014 upon the issuance of the convertible preferred stock. In February 2014, in connection with the first equity round of financing and issuance of the Series A convertible preferred stock, the noteholders exercised their option to convert their Notes into 207,664 shares of common stock and accrued interest was paid in cash to the noteholders. The accreted interest expense related to the discount on the Notes was $1,443 for the period from January 1, 2014 to the conversion date of the Notes. Upon conversion, the entire remaining debt discount of $4,071 was recorded as interest expense.

In connection with the Notes, the Company issued warrants to the noteholders, which became exercisable to purchase an aggregate of 207,664 shares of common stock as of the issuance of the first equity round of financing (the "Warrants"). The Warrants have a $2.53 exercise price, are fully exercisable from the initial date of the first equity round of financing, and have a five-year term subsequent to that date.

2014 Convertible Notes

On June 2, 2014, pursuant to a convertible note purchase agreement, the Company issued convertible promissory notes in the aggregate principal amount of $300,000 to two accredited investors, including a convertible promissory note for $200,000 to a board member to which Series A preferred stock was sold. These notes accrued interest at 3% per annum and automatically were to mature on June 1, 2015. Interest expense for the year ended December 31, 2015 was $3,237 and is included in interest expense in the statement of operations and comprehensive loss. Accrued interest is $8,507 and is included in accrued liabilities in the balance sheet. All interest was to be paid in cash upon maturity. Upon the closing of the IPO, the outstanding principal amount automatically converted into 53,571 shares common stock at $5.60, as amended in March 2015. Upon issuance, the Company analyzed the beneficial nature of the conversion terms and determined that a beneficial conversion feature ("BCF") existed because the effective conversion price on issuance of the notes was less than the fair value at the time of the issuance. The Company calculated the value of the BCF using the intrinsic method and recorded a BCF of $75,000 as a discount to notes payable and to additional paid-in capital. For the year ended December 31, 2015, the Company amortized $31,250 of the discount as interest expense in the statements of operations and comprehensive loss.

On July 16, 2014, pursuant to a convertible note purchase agreement, the Company issued a convertible promissory note in the principal amount of $150,000 to an accredited investor. This note accrued interest at 3% per annum and automatically was to mature on June 1, 2015. Interest expense for the year ended December 31, 2015 was $1,627 and is included in interest expense in the statements of operations and comprehensive loss. Accrued interest is $3,711 and is included in accrued liabilities in the balance sheet. All interest was to be paid in cash upon maturity. Upon the closing of the IPO, the outstanding principal amount automatically converted into 26,785 shares of common stock at $5.60, as amended in March 2015. Upon issuance, the Company analyzed the beneficial nature of the conversion terms and determined that a BCF existed because the effective conversion price was less than the fair value at the time of the issuance. The Company calculated the value of the BCF using the intrinsic method and recorded a BCF of $37,500 as a discount to the notes payable and to additional paid-in capital. For the year ended December 31, 2015, the Company amortized $17,857 of the discount as interest expense in the statements of operations and comprehensive loss.

In connection with the Transfer Agreement (Note 6) the Company issued fully vested and immediately exercisable warrants to the Manufacturer to purchase 16,666 shares of common stock at 90% of the IPO price, amended to $6.30 in March 2015, for a period of five years. The fair value of the warrants, $37,840, was recorded as research and development expense and additional paid-in capital in June 2014. The warrants were originally valued using the Black-Scholes model with the following assumptions: stock price of $4.83, exercise price of $4.35, term of five years, volatility of 49%, dividend yield of 0%, and risk-free interest rate of 1.64%.

On December 23, 2014, pursuant to a convertible note purchase agreement, the Company issued convertible promissory notes in the aggregate principal amount of $650,000 to three accredited investors, including a convertible promissory note for $250,000 to the same board member to which the June 2, 2014 $200,000 convertible promissory note was issued and to which Series A preferred stock was sold. These notes accrued interest at 12% per annum and became payable within thirty days following the IPO. Interest expense for the year ended December 31, 2015 was $28,210 and is included in interest expense in the statements of operations and comprehensive loss. Accrued interest is $30,132 and is included in accrued liabilities in the balance sheet. All interest was to be paid in cash upon maturity. Upon consummation of the Company's IPO, the noteholders converted the notes into 116,070 shares of common stock at a conversion price equal to 80% of the IPO price, amended to $5.60 in March 2015. In connection with these notes, the Company also issued the lenders a fully vested warrant to purchase shares of the Company's common stock at an exercise price equal to 80% of the IPO price, amended to $5.60 in March 2015. These warrants entitle the noteholders to purchase 58,035 shares of common stock. The fair value of the warrants, $147,943, was recorded as a debt discount and liability at December 23, 2014. The Company amortized $141,890 of this discount in the year ended December 31, 2015 which has been recorded as interest expense in the Company's statements of operations and comprehensive loss. The warrants were originally valued using the Black-Scholes model with the following assumptions: stock price of $4.59, exercise price of $4.15, term of three years expiring December 2017, volatility of 49%, dividend yield of 0%, and risk-free interest rate of 1.10%. Based on the circumstances, the value derived using the Black-Scholes model approximated that which would be obtained using a lattice model. The debt discount was amortized as interest expense over the one hundred ninety days from issuance of the notes through their first maturity date of July 31, 2015, beginning in January 2015. The Company analyzed the beneficial nature of the conversion terms and determined that a BCF existed because the effective conversion price was less than the fair value at the time of the issuance. The Company calculated the value of the BCF using the intrinsic method. A BCF of $502,057 was recorded as a discount to the notes payable and to additional paid-in capital. For the year ended December 31, 2015, the Company amortized $484,329 of the BCF as interest expense in the statements of operations and comprehensive loss.

2015 Convertible Notes

In February 2015, the Company issued convertible promissory notes to two accredited investors in the aggregate principal amount of $250,000. These notes were issued pursuant to the convertible note purchase agreement dated December 23, 2014. In connection with the issuance of the notes, the Company issued the lenders warrants to purchase 22,320 shares at $5.60 per share, which expire December 31, 2017. Principal and interest of $103,912 was paid in May 2015 for $100,000 of these notes. The Company analyzed the beneficial nature of the conversion terms and determined that a BCF existed because the effective conversion price was less than the fair value at the time of the issuance. The Company calculated the value of the BCF using the intrinsic method. A BCF of for the full face value was recorded as a discount to the notes payable and to additional paid-in capital. For the years ended December 31, 2016 and 2015, the Company amortized $0 and $250,000 of the BCF as interest expense in the Company's statement of operations and comprehensive income.

Extinguishment of debt

The remaining outstanding note of $150,000 is payable to the investor at an effective simple interest rate of 12% per annum, and was due in full on July 31, 2016. On July 28, 2016, the Company entered into an amendment to delay the repayment of the principal and related interest under the terms of the remaining note from July 31, 2016 to October 31, 2016. On November 8, 2016, the Company entered into an amendment to extend the maturity date of the remaining note from October 31, 2016 to January 1, 2017. In exchange for the extension of the maturity date, on November 8, 2016, the Company's board of directors granted the lendor a warrant to purchase 120,000 shares of the Company's common stock for $0.01 per share. The warrant is exercisable at any time on or before July 28, 2022, the expiration date of the warrant.

The amendment and related warrant issuance resulted in the Company treating the debt as having been extinguished and replaced with new debt for accounting purposes due to meeting the 10% cash flow test. The Company calculated a loss on the extinguishment of debt of $108,000, or the equivalent to the fair value of the warrants granted, which is included in other expense in the Company's statements of operations and comprehensive loss.

The $150,000 note is included in notes payable in the Company's balance sheet. The Company has accrued interest of $33,929 and $15,880, which is included in accrued liabilities in the Company's balance sheet as of December 31, 2016 and 2015, respectively, and incurred $18,049 and $15,880 in interest expense in the years ended December 31, 2016 and 2015, respectively.

On December 28, 2016, the Company entered into an amendment to extend the maturity date of the note from January 1, 2017 to January 31, 2017. On January 31, 2017, the Company entered into an amendment to further extend the due date of the $150,000 convertible note payable from January 31, 2017 to January 1, 2018.

In March 2015, the Company entered into a non-binding letter of intent with an investor. In connection therewith, the investor paid the Company $1.0 million. At March 31, 2015, the Company had recorded this amount as a loan advance on the balance sheet. In April 2015, the investor purchased $1.0 million of convertible promissory notes from the Company, the terms of which provided that such notes were to be converted into shares of the Company's common stock upon the closing of an IPO at a conversion price of $5.60 per share. In connection with the purchase of the notes, the Company issued the investor a warrant to purchase 89,285 shares at $5.60 per share, which expires December 31, 2017. The notes accrued simple interest of 12% per annum and, upon consummation of the Company's IPO in May 2015, converted into 178,571 shares of the Company's common stock. The Company analyzed the beneficial nature of the conversion terms and determined that a BCF existed because the effective conversion price was less than the fair value at the time of the issuance. The Company calculated the value of the BCF using the intrinsic method. A BCF of for the full face value was recorded as a discount to the notes payable and to additional paid-in capital. For the year ended December 31, 2015, the Company amortized $1,000,000 of the BCF as interest expense in the Company's statements of operations and comprehensive income. The Company has accrued interest of $17,753, which is included in accrued liabilities in the Company's balance sheet, and has incurred $17,753 and $15,880 in interest expense in the years ended December 31, 2016 and 2015, respectively.

The outstanding convertible notes payable obligation was $150,000 as of December 31, 2016 and 2015.

Interest expense on the convertible notes for the years ended December 31, 2016 and 2015 was as follows:

	Years Ended December 31,
	2016		2015
Nominal Interest	$	18,049	$	70,619
Amortization of debt discount		—		1,925,326

	$	18,049	$	1,995,945

Interest payable on the convertible notes at December 31, 2016 and 2015 was as follows:

	December 31, 2016		December 31, 2015
Interest Payable:	$	94,048	$	75,999

Notes Payable—Bridge Loans

On October 30, 2014, the Company entered into a standby bridge financing agreement with two lenders, which was amended and restated on December 3, 2014, which provided a loan commitment in the aggregate principal amount of $1.0 million (the "Bridge"). Proceeds to the Company were net of a $100,000 debt discount under the terms of the Bridge and net of $104,000 of debt issuance costs. This debt discount and debt issuance costs were recorded as interest expense using the effective interest method, over the six month term of the Bridge. The Bridge became payable upon the IPO. The Bridge was repaid in May 2015, including interest thereon in an amount of $1,321,600. In connection with the Bridge, the lenders were granted warrants to purchase 178,569 shares of the Company's common stock determined by dividing $1.0 million by the exercise price of 80% of the IPO price, amended to $5.60 in March 2015. The fair value of the warrants, $505,348, was originally recorded as a debt discount and liability at December 3, 2014. The warrants were originally valued using the Black-Scholes model with the following assumptions: stock price of $5.01, exercise price of $5.23, term of five years expiring December 2019, volatility of 63%, dividend yield of 0%, and risk-free interest rate of 1.61%. Based on the circumstances, the value derived using the Black-Scholes model approximated that which would be obtained using a lattice model. The debt discount was recorded as interest expense over the six month term of the Bridge. Of the aggregate debt discount of $605,348 (warrants and original $100,000 discount), $521,291 was recorded as interest expense during the year ended December 31, 2015. Additional financing costs of $104,000 were incurred related to the Bridge and deferred on closing. These were recognized as interest expense over the six-month term of the Bridge using the effective interest method. The Company amortized the remaining $86,667 of these deferred financing charges by the end of May 2015 was recorded the amortized amounts as interest expense. The Company fully extinguished the debt and accrued interest in May 2015.

Interest expense on the notes payable-bridge loans for the years ended December 31, 2016 and 2015 was as follows:

	Years Ended December 31,
	2016		2015
Nominal Interest	$	—	$	100,000
Amortization of debt discount		—		521,291
Repayment premium		—		201,600
Debt issuance costs		—		86,667

	$	—	$	909,558

Standby Line of Credit

In August 2014, the Company entered into a standby line of credit with an accredited investor for up to $1.0 million pursuant to a Line of Credit and Loan Agreement dated August 26, 2014. In connection with the entry into the standby line of credit, the Company issued the lender a fully vested warrant to purchase 33,333 shares of common stock at an exercise price equal to 80% of the IPO price, amended to $5.60 in March 2015, which expires in August 2016. The fair value of the warrants, $114,300, was recorded as interest expense and additional paid-in capital in August 2014. The warrants were originally valued using the Black-Scholes model with the following assumptions: stock price of $8.00, exercise price of $6.40, term of two years, volatility of 52%, dividend yield of 0%, and risk-free interest rate of 0.52%. The line of credit expired on March 31, 2015 and there were no drawdowns under the facility. The warrants expired in August 2016.

Long-term Debt

In August 2015, the Company entered into a loan and security agreement with a lender for up to $8.0 million, which provided for an initial loan commitment of $6.0 million. The loan agreement requires the Company to maintain $4.5 million of the proceeds in cash, which may be reduced or eliminated on the achievement of certain milestones. An additional $2.0 million is available contingent on the achievement of certain further milestones. The agreement has a term of three years, with interest only payments through February 29, 2016. Thereafter, principal and interest payments will be made with an interest rate of 9.9%. Additionally, there will be a balloon payment of $560,000 on August 1, 2018. This amount is being recognized over the term of the loan agreement and the effective interest rate, considering the balloon payment, is 15.0%. Proceeds to the Company were net of a $134,433 debt discount under the terms of the loan agreement. This debt discount is being recorded as interest expense, using the interest method, over the term of the loan agreement. Under the agreement, the Company is entitled to prepay principal and accrued interest upon five days prior notice to the lender. In the event of prepayment, the Company is obligated to pay a prepayment charge. If such prepayment is made during any of the first twelve months of the loan agreement, the prepayment charge will be (a) during such time as the Company is required to maintain a minimum cash balance, 2% of the minimum cash balance amount plus 3% of the difference between the amount being prepaid and the minimum cash balance, and (b) after such time as the Company is no longer required to maintain a minimum cash balance, 3% of the amount being prepaid. If such prepayment is made during any time after the first twelve months of the loan agreement, 1% of the amount being prepaid.

On April 21, 2016, the loan and security was amended upon which the Company repaid $1.5 million of the debt out of restricted cash. The amendment modified the repayment amortization schedule providing a four-month period of interest only payments for the period from May through August 2016.

As of December 31, 2016 and 2015, the net long-term debt obligation was as follows:

	December 31, 2016			December 31, 2015
Debt and unpaid accrued end-of-term payment	$	3,894,320		$	6,115,797
Unamortized note discount		(42,493	)		(106,635	)
Unamortized debt issuance costs		(114,626	)		(206,235	)

Net debt obligation	$	3,737,201		$	5,802,927


Current portion of long-term debt	$	1,919,675		$	1,707,899
Long-term debt, net of discount		1,817,526		$	4,095,028

Total	$	3,737,201		$	5,802,927

Future principal payments under the long-term debt are as follows:

Years ending December 31	Amount
2017	$	2,032,048
2018		1,479,246

Total future principal payments		3,511,294
2018 end-of-term payment		560,000

		4,071,294
Less: unaccreted end-of-term payment at December 31, 2016		(176,974	)

Debt and unpaid accrued end-of-term payment	$	3,894,320

The obligation at December 31, 2015 includes an end-of-term payment of $560,000, which accretes over the life of the loan as interest expense. As a result of the debt discount and the end-of-term payment, the effective interest rate for the loan differs from the contractual rate.

Interest expense on the long-term debt for the years ended December 31, 2016 and 2015 was as follows:

	December 31, 2016		December 31, 2015
Nominal Interest	$	457,448	$	224,400
Amortization of debt discount		64,142		27,798
Accretion of end-of-term payment		267,230		115,797
Debt issuance costs		178,713		43,789

	$	967,533	$	411,784

At the IPO, the Company's outstanding warrants to purchase convertible preferred stock were all converted to warrants to purchase common stock.

Warrants

On November 22, 2016, the Company entered into a Securities Purchase Agreement, or the 2016 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities to such investors in a private placement transaction, which we refer to herein as the 2016 Private Placement. In the 2016 Private Placement, the Company sold an aggregate of 1,666,668 shares of the Company's common stock at a price of $0.60 per share for gross proceeds of approximately $1.0 million. The investors in the 2016 Private Placement also received (i) warrants to purchase up to an aggregate of 1,666,668 shares of the Company's common stock, at an exercise price of $0.75 per share, or the Series A Warrants, and the Placement Agent received warrants to purchase 133,333 shares of our common stock in lieu of cash for service fees with the same terms as the investors; (ii) warrants to purchase up to an aggregate 1,666,668 shares of the Company's common stock, at an exercise price of $0.90 per share, or the Series B Warrants, and (iii) warrants to purchase up to an aggregate 1,666,668 shares of our common stock, at an exercise price of $1.00 per share, or the Series C Warrants and, together with the Series A Warrants and the Series B Warrants, the 2016 Warrants.The warrants were granted in three series with different terms. The warrants were valued using the Black-Scholes-Merton warrant pricing model as follows:


	•	Series A Warrants and Placement Agent Warrants: 1,666,668 warrant shares with a strike price of $0.75 per share and an expiration date of May 29, 2022; and 133,333 warrant shares to the placement agent with a strike price of $0.75 and an expiration date of May 29, 2022; the expected life is 5.5 years, the volatility is 71.92% and the risk free rate is 1.87% in valuing these warrants.
	•	Series B Warrants: 1,666,668 warrant shares with a strike price of $0.90 per share and an expiration date of November 29, 2017; the expected life is one year, the volatility is 116.65% and the risk free rate is 0.78% in valuing these warrants.
	•	Series C Warrants: 1,666,668 warrant shares with a strike price of $1.00 per share and an expiration date of May 29, 2018; the expected life is 1.5 years, the volatility is 116.92% and the risk free rate is 0.94%.

The warrant valuation date was November 29, 2016 and the closing price of $0.69 per share was used in determining the fair value of the warrants. The series A warrants and placement agent warrants were valued at $756,001 and were classified as a warrant liability in the Company's balance sheet. The series A warrants and placement agent warrants were revalued on December 31, 2016 at $799,201 which is included in the Company's balance sheet, and the $43,200 increase is included in the Company's statements of operations and comprehensive loss. The strike price was $0.75 per share, the expected life was 5.41 years, the volatility was 73.62% and the risk free rate was 2.0%. The series B and C warrants were classified as equity, and as such were not subject to revaluation at year end. Costs incurred in connection with the issuance were allocated based on the relative fair values of the Series A and the Series B and C warrants.

The Company's warrant activity is summarized as follows:

	December 31, 2016			December 31, 2015
Beginning balance at January 1		748,872			494,267
Warrants granted		5,253,337			254,605
Warrants cancelled		(33,333	)		—

Ending balance at December 31		5,968,876			748,872

Stockholders' Equity

12 Months Ended

Dec. 31, 2016

Stockholders' Equity

Stockholders' Equity

9. Stockholders' Equity

Common Stock

The Company's second amended and restated certificate of incorporation authorizes the Company to issue 50,000,000 shares of common stock $0.0001 par value. The holders of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders. The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of shares of capital stock of the Company representing a majority of the votes represented by all shares (including Preferred Stock) entitled to vote.

In February 2016, the Company completed a secondary public offering of its common stock. In connection with its secondary public offering, the Company issued and sold 2,000,000 shares of common stock at a price to the public of $2.50 per share. As a result of the secondary public offering, the Company received $4.1 million in net proceeds, after deducting underwriting discounts and commissions of $373,011 and offering expenses of $496,887.

In June 2016, the Company entered into a common stock purchase agreement with a private investor (the "CSPA"), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the investor is committed to purchase up to an aggregate of $15.0 million of the Company's common stock over the approximately 30-month term of the agreement. Upon execution of the CSPA, the Company sold 222,222 shares of its common stock to the investor at $2.25 per share for net proceeds of $394,534, reflecting gross proceeds of $500,000 and offering expenses of $105,398. In consideration for entering into the CSPA, the Company issued 456,667 shares of its common stock to the investor. Concurrently with entering into the CSPA, the Company also entered into a registration rights agreement with the investor (the "Registration Agreement"), in which the Company agreed to file one or more registration statements, as permissible and necessary to register under the Securities Act of 1933, as amended, the sale of the shares of the Company's common stock that have been and may be issued to the investor under the CSPA. On June 22, 2016 and September 22, 2016, the Company filed registration statements on Form S-1 (File Nos. 333-212173 and 333-213751) pursuant to the terms of the Registration Agreement, which registration statements were declared effective on July 8, 2016 and October 5, 2016, respectively. In the year ended December 31, 2016, pursuant to the CSPA, the Company sold an additional 1,348,601 shares of the Company's common stock in exchange for $2,176,700 of cash proceeds. Of the $15.0 million available under the CSPA, the Company has received $2,676,700 as of December 31, 2016. Under the CSPA, the Company cannot issue more than the 2,027,490 shares of common stock already issued unless the price per share is $1.32 (the closing price on the date that the CSPA was signed).

In October 2016, the Company entered into a Common Stock Purchase Agreement with an existing private investor. Upon execution of the agreement the Company sold 170,455 shares of its common stock in exchange for $150,000 in cash proceeds.

On November 22, 2016, the Company entered into a Securities Purchase Agreement, or the 2016 Purchase Agreement, with certain institutional investors, pursuant to which the Company sold securities to such investors in a private placement transaction, which is referred to herein as the 2016 Private Placement. In the 2016 Private Placement, the Company sold an aggregate of 1,666,668 shares of its common stock at a price of $0.60 per share for net proceeds of $677,224 or gross proceeds of approximately $1.0 million less $322,777 in issuance costs. The investors in the 2016 Private Placement also received (i) warrants to purchase up to an aggregate of 1,666,668 shares of our common stock, at an exercise price of $0.75 per share, or the Series A Warrants, (ii) warrants to purchase up to an aggregate 1,666,668 shares of our common stock, at an exercise price of $0.90 per share, or the Series B Warrants, and (iii) warrants to purchase up to an aggregate 1,666,668 shares of our common stock, at an exercise price of $1.00 per share, or the Series C Warrants and, together with the Series A Warrants and the Series B Warrants, the 2016 Warrants. The issuance costs were allocated to common stock, series A warrants, and Series B and C warrants based on the relative fair value of each:

Instruments	Fair Value		% Allocation			Issuance Costs (allocated)
Common Stock	$	156,522		16	%	$	50,522
Warrants (Series A)		700,001		70	%		225,944
Warrants (Series B and C)		143,478		14	%		46,311

Total	$	1,000,001		100	%	$	322,777

Common stock of a net $106,000 (fair value less issuance costs) was included in equity in the company's balance sheet. Series A warrants of $756,001, consisting of the series A warrants of $700,001 and the series A placement agent warrants of $56,000, are included in current liabilities in the company's balance sheet and the $225,944 of issuance cost was expensed and is in general and administrative expense on the company's statement of operations and comprehensive loss. Series B and C warrants of a net $97,167 (fair value less issuance costs) were classified in equity in the company's balance sheet.

In exchange for the extension of the maturity date of the outstanding 2015 Convertible Note, on, November 8, 2016, the Company's board of directors granted the lender a warrant to purchase 120,000 shares of the Company's common stock for $0.01 per share. The warrant is exercisable at any time on or before July 28, 2022, the expiration date of the warrant. The amendment and related warrant issuance resulted in the Company treating the debt as having been extinguished and replaced with new debt for accounting purposes due to meeting the 10% cash flow test. The Company calculated a loss on the extinguishment of debt of $108,000, or the equivalent to the fair value of the warrants granted, which is included in other expense in the Company's statements of operations and comprehensive loss. The warrants were valued on November 8, 2016 using the Black-Scholes-Merton model with the following assumptions: stock price of $0.91, exercise price of $0.01, term of 5.72 years expiring July 2022, volatility of 70.35%, dividend yield of 0%, and risk-free interest rate of 1.45%.

As of December 31, 2016 and 2015, the Company had reserved shares of common stock for issuance as follows:

	December 31, 2016		December 31, 2015
Options issued and outstanding		2,571,220		919,506
Options available for grant		39,988		106,833
RSUs issued and outstanding		20,789		55,536
Warrants issued and outstanding		5,968,876		748,872
Convertible notes		67,655		26,785

Total		8,668,528		1,857,532

Preferred Stock

The Company's second amended and restated certificate of incorporation authorizes the Company to issue 10,000,000 shares of preferred stock $0.0001 par value. No shares of preferred stock were issued or outstanding at December 31, 2016 or December 31, 2015.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock Incentive Plans

12 Months Ended

Dec. 31, 2016

Stock Incentive Plans

Stock Incentive Plans

10. Stock Incentive Plans

2013 Equity Incentive Plan

Effective November 1, 2013, the Company's board of directors and sole stockholder adopted the Jaguar Animal Health, Inc. 2013 Equity Incentive Plan (the "2013 Plan"). The 2013 Plan allows the Company's board of directors to grant stock options, restricted stock awards and restricted stock unit awards to employees, officers, directors and consultants of the Company. As of December 31, 2013, the Company had reserved 300,000 shares of its common stock for issuance under the 2013 Plan. In April 2014, the board of directors amended the 2013 Plan to increase the shares reserved for issuance to 847,533 shares. Following the effective date of the IPO and after effectiveness of any grants under the 2013 Plan that were contingent on the IPO, no additional stock awards will be granted under the 2013 Plan. Outstanding grants continue to be exercisable, however any unissued shares under the plan and any forfeitures of outstanding options do not rollover to the 2014 Stock Incentive Plan.

2014 Stock Incentive Plan

Effective May 12, 2015, the Company adopted the Jaguar Animal Health, Inc. 2014 Stock Incentive Plan ("2014 Plan"). The 2014 Plan provides for the grant of options, restricted stock and restricted stock units to eligible employees, directors and consultants to purchase the Company's common stock. The Company reserved 333,333 shares of common stock for issuance pursuant to the 2014 Plan. The Company added 162,498 shares to the plan in accordance with the Plan that provides for automatic share increases on the first day of each fiscal year in the amount of 2% of the outstanding number of shares of the Company's common stock on last day of the preceding calendar year. The 2014 Plan replaces the 2013 Plan except that all outstanding options under the 2013 Plan remain outstanding until exercised, cancelled or until they expire.

In July 2015, the Company amended the 2014 Plan reserving an additional 550,000 shares under the plan contingent upon approval by the Company's stockholders at the June 2016 annual stockholders meeting. In June 2016, the Company amended the 2014 Plan once again, modifying the increase from 550,000 shares to 1,550,000 shares, which was approved at the 2016 annual stockholders meeting.

Stock Options and Restricted Stock Units ("RSUs")

The following table summarizes incentive plan activity for the years ended December 31, 2016 and 2015:

	Shares Available for Grant			Stock Options Outstanding			RSUs Outstanding			Weighted Average Stock Option Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
2013 Equity Incentive Plan Balance—December 31, 2014		119,077			659,554			68,902		$	2.67
Additional shares authorized		—
Options granted		(176,364	)		176,364			—		$	7.00
Options cancelled		95,784			(95,784	)		—		$	2.53
Options available for grant cancelled upon IPO		(51,863	)		—
Options cancelled post-IPO not rolled back into the 2013 Plan		—			(42,128	)
Options exercised		—			(5,000	)		—		$	2.53
RSUs granted		(1,484	)		—			1,484
RSUs cancelled		14,850			—			(14,850	)

2013 Equity Incentive Plan Balance—December 31, 2015		—			693,006			55,536		$	3.74
2014 Stock Stock Plan Balance—December 31, 2014		—
Shares authorized		333,333
Options granted		(241,500	)		241,500					$	4.32
Options cancelled		15,000			(15,000	)				$	5.09

Combined Incentive Plan Balance—December 31, 2015		106,833			919,506			55,536		$	3.87		8.81	$	—
2013 Equity Incentive Plan Activity:
Options cancelled not rolled back into the 2013 Plan					(127,629	)				$	4.19
RSUs vested and released								(27,768	)
RSUs cancelled								(6,979	)
2014 Stock Incentive Plan Activity:
Additional shares authorized		1,712,498
Options granted		(1,927,121	)		1,927,121					$	1.97
Options cancelled		147,778			(147,778	)				$	2.28

Combined Incentive Plan Balance—December 31, 2016		39,988			2,571,220			20,789		$	2.52		8.77


Options vested and exercisable—December 31, 2016					983,147					$	3.41		8.25	$	—


Options vested and expected to vest—December 31, 2016					2,163,246					$	2.52		8.73	$	—

The weighted average grant date weighted average fair value of stock options granted was $0.86 and $2.90 per share during the years ended December 31, 2016 and 2015.

The number of option shares that vested in the years ended December 31, 2016 and 2015 was 655,481 shares and 413,063 shares, respectively. The grant date weighted average fair value of option shares that vested in the years ended December 31, 2016 and 2015 was $722,134 and $893,974, respectively.

The grant date weighted-average fair value of options exercised was $0.43 in the year December 31, 2015 of which there was no intrinsic value. No options were exercised in the year ended December 31, 2016.

The Company granted RSUs in 2014 and 2015 under the 2013 Equity Incentive Plan. The units granted vest upon the occurrence of both a liquidity event and satisfaction of the service-based requirement. The time-based vesting provides that 50% of the RSU will vest on January 1, 2016 and the remaining 50% vest on July 1, 2017. The Company began recording stock-based compensation expense relating to the RSU grants effective May 18, 2015, the date of the Company's initial public offering, and the date the liquidity condition was met. The stock-based compensation expense is based on the grant date fair value which is the equivalent to the fair market value on the date of grant, and is amortized over the vesting period using the straight-line method, net of estimated forfeitures. On January 1, 2016, the Company issued 17,546 shares of its common stock in exchange for 27,768 vested and released RSUs, net of 10,172 RSU shares used to pay withholding taxes.

Stock-Based Compensation

The following table summarizes stock-based compensation expense related to stock options and RSUs for the three months ended December 31, 2016 and 2015, and are included in the statements of operations and comprehensive loss as follows:

	Years Ended December 31,
	2016		2015
Research and development expense	$	181,489	$	472,145
Sales and marketing expense		73,679		54,115
General and administrative expense		462,759		465,905

Total	$	717,927	$	992,165

As of December 31, 2016, the Company had $1,263,950 of unrecognized stock-based compensation expense for options and restricted stock units outstanding, which is expected to be recognized over a weighted-average period of 1.9 years.

The estimated grant-date fair value of employee stock options was calculated using the Black-Scholes option-pricing model using the following assumptions:

	Years Ended December 31,
	2016	2015
Weighted-average volatility	66.25 - 72.08%	55.43 - 61.51%
Weighted-average expected term (years)	5.00 - 5.82	5.15 - 5.82
Risk-free interest rate	1.10 - 2.15%	1.60 - 1.84%
Expected dividend yield	—	—

The estimated grant-date fair value of non-employee stock options was calculated using the Black-Scholes option-pricing model using the following assumptions:

	Years Ended December 31,
	2016	2015
Weighted-average volatility	78.30 - 80.04%		76.63	%
Weighted-average expected term (years)	9.19 - 10.00		9.69
Risk-free interest rate	1.32 - 2.46%		2.25	%
Expected dividend yield	—		—

Income Taxes

12 Months Ended

Dec. 31, 2016

Income Taxes

Income Taxes

12. Income Taxes

The Company's loss before provision for income taxes during the years ended December 31, 2016 and 2015, was a domestic loss of $14,733,780 and $16,291,550, resepctively.

Due to continued losses for the year ending December 31, 2016, and a full valuation allowance, the Company has not recorded a provision for income taxes for the years ending December 31, 2016 or 2015.

The components of the provision for income taxes during the years ended December 31, 2016 and 2015 is as follows:

	December 31, 2016			December 31, 2015
Current:
Federal	$	—		$	—
State		—			—
Foreign		—			—

Total Current		—			—

Deferred:
Federal		(4,387,544	)		(4,197,007	)
State		(1,249,149	)		(587,696	)
Foreign		—			—

Total Deferred		(5,636,693	)		(4,784,703	)
Valuation Allowance		5,636,693			4,784,703

Total Provision for Income Taxes	$	—		$	—

The Company's effective tax during the years ended December 31, 2016 and 2015, differed from the federal statutory rate as follows:

	December 31, 2016			December 31, 2015
Statutory Rate		(34.0	)%		(34.0	)%
State Taxes		(5.6	)%		(3.6	)%
Tax Credits		(0.5	)%		5.2	%
Other		1.8	%		1.7	%
Valuation Allowance		38.3	%		30.7	%

Effective Tax Rate		0.0	%		0.0	%

Net deferred tax assets as of December 31, 2016 and 2015 consist of the following:

	December 31, 2016			December 31, 2015
Non-current Deferred Tax Assets:
Net Operating Costs	$	9,626,610		$	7,459,489
Tax Credits		374,605			261,851
Stock Compensation		297,438			188,602
Fixed Assets and Intangibles		3,700,557			470,577
Other		93,434			75,432

		14,092,644			8,455,951
Valuation Allowance		(14,092,644	)		(8,455,951	)

Net Non-current Deferred Tax Assets	$	—		$	—

A valuation allowance is provided when it is more likely than not that the deferred tax assets will not be realized. The Company has established a valuation allowance to offset net deferred tax assets as of December 31, 2016 and 2015, due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets.

The valuation allowance increased by $5,636,693 during the year ended December 31, 2016.

As of December 31, 2016, the Company had federal and California net operating loss carryovers of approximately $24,543,368 and $17,103,817, respectively. The federal and California net operating losses will begin to expire in 2033.

As of December 31, 2016, the Company had federal and California research credit carryovers of approximately $279,793 and $285,554, respectively. The federal research credits will begin to expire in 2033. The California research credits carry forward indefinitely.

Utilization of the domestic NOL and tax credit forwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by the Internal Revenue Code Section 382, as well as similar state provisions. In general, an "ownership change," as defined by the code, results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders or public groups. Any limitation may result in expiration of all or a portion of the NOL or tax credit carryforwards before utilization.

In November 2015, the FASB issued Accounting Standards Update 2015-17, which simplifies the presentation of deferred income taxes by requiring that deferred tax assets and liabilities be presented as non-current. The standard impacts presentation only. The Company elected to early adopt the standard on a retrospective basis effective December 31, 2015, and all deferred tax assets and liabilities are classified as non-current on the Company's consolidated balance sheets. Adoption of this ASU had no effect on the Company's balance sheet for 2015 as presented.

Uncertain Tax Positions

The Company has adopted the provisions of ASC 740, "Income Taxes Related to Uncertain Tax Positions." Under these principals, tax positions are evaluated in a two-step process. The Company first determines whether it is more-likely-than-not that a tax positions will be sustained upon examination. If a tax position meets the more-likely-than-not recognition threshold it is then measured to determine the amount of benefit to be recognized in the financial statements. The tax position is measured as the largest amount of benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement.

The following is a reconciliation of the beginning and ending amount of our total gross unrecognized tax benefit liabilities:

	December 31, 2016		December 31, 2015
Gross Unrecognized Tax Benefit—Beginning Balance	$	78,930	$	31,006
Increases Related to Tax Positions from Prior Years		—		5,920
Increases Related to Tax Positions Taken During t the Current Year		34,143		42,004

Gross Unrecognized Tax Benefit—Beginning Balance	$	113,073	$	78,930

There are no liabilities from unrecognized tax benefits included in the Company's balance sheet as of December 31, 2016 and 2015, and therefore the Company has not accrued for any penalties or interest.

The Company files income tax returns in the United States and various states, where the statute of limitations are 3 years and 4 years, respectively. The Company remains open for audit by the United States Internal Revenue Service and states state tax jurisdictions since inception.

The Company is not currently under examination by income tax authorities in federal or state jurisdictions.

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2016
Summary of Significant Accounting Policies
Basis of Presentation	Basis of Presentation The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP").
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company's management to make judgments, assumptions and estimates that affect the amounts reported in its financial statements and the accompanying notes. The accounting policies that reflect the Company's more significant estimates and judgments and that the Company believes are the most critical to aid in fully understanding and evaluating its reported financial results are valuation of stock options; valuation of warrant liabilities; impairment of long lived assets; useful lives for depreciation; valuation adjustments for excess and obsolete inventory; deferred taxes and valuation allowances on deferred tax assets; and evaluation and measurement of contingencies. Those estimates could change, and as a result, actual results could differ materially from those estimates.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs are costs incurred in filings of registration statements with the Securities and Exchange Commission. These deferred offering costs are offset against proceeds received upon the closing of the offerings. Deferred costs of $143,231 as of December 31, 2015 include legal, accounting and filing fees associated with the follow-on registration offering as more fully described in Note 9. Deferred costs of $72,710 as of December 31, 2016 include legal, accounting and filing fees associated with the Company's registration of unissued shares in the CSPA.
Concentration of Credit Risk and Cash and Cash Equivalents	Concentration of Credit Risk and Cash and Cash Equivalents Cash is the financial instrument that potentially subjects the Company to a concentration of credit risk as cash is deposited with a bank and cash balances are generally in excess of Federal Deposit Insurance Corporation ("FDIC") insurance limits. The carrying value of cash approximates fair value at December 31, 2016 and 2015.
Fair Values	Fair Values The Company's financial instruments include, cash and cash equivalents, accounts payable, accrued expenses, amounts due to Napo, the former parent, warrant liabilities, and debt. Cash is reported at fair value. The recorded carrying amount of accounts payable, accrued expenses and amounts due to Napo approximates their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for bank loans with similar terms and maturities. See Note 3 for the fair value measurements, and Note 7 for the fair value of the Company's warrant liabilities.
Restricted Cash	Restricted Cash On August 18, 2015, the Company entered into a long-term loan and security agreement with a lender for up to $8.0 million, which provided for an initial loan commitment of $6.0 million. The loan agreement required the Company to maintain a base minimum cash balance of $4.5 million until the Company met certain milestones and/or when the Company begins making principal payments. On December 22, 2015, the Company achieved certain milestones and the base minimum cash balance was reduced to $3.0 million. Aggregate principal payments of $2.5 million further reduced the restricted cash balance to $511,294 as of December 31, 2016. Restricted cash has been classified within current assets as restrictions will be fully released on April 1, 2017.
Inventories	Inventories Inventories are stated at the lower of cost or market. The Company calculates inventory valuation adjustments when conditions indicate that the net realizable value is less than cost due to physical deterioration, usage, obsolescence, reductions in estimated future demand or reduction in selling price. Inventory write-downs are measured as the difference between the cost of inventory and estimated net realizable value. There have been no write-downs to date.
Property and Equipment	Property and Equipment Equipment is stated at cost, less accumulated depreciation. Equipment begins to be depreciated when it is placed into service. Depreciation is calculated using the straight-line method over the estimated useful lives of 3 to 10 years. Expenditures for repairs and maintenance of assets are charged to expense as incurred. Costs of major additions and betterments are capitalized and depreciated on a straight-line basis over their estimated useful lives. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed of are removed from the accounts and any resulting gain or loss is included in income (loss) from operations.
Long-Lived Assets	Long-Lived Assets The Company regularly reviews the carrying value and estimated lives of all of its long-lived assets, including property and equipment to determine whether indicators of impairment may exist that warrant adjustments to carrying values or estimated useful lives. The determinants used for this evaluation include management's estimate of the asset's ability to generate positive income from operations and positive cash flow in future periods as well as the strategic significance of the assets to the Company's business objectives. Should an impairment exist, the impairment loss would be measured based on the excess of the carrying amount over the asset's fair value. The Company has not recognized any impairment losses through December 31, 2016.
Research and Development Expense	Research and Development Expense Research and development expense consists of expenses incurred in performing research and development activities including related salaries, clinical trial and related drug and non-drug product costs, contract services and other outside service expenses. Research and development expense is charged to operating expense in the period incurred.
Revenue Recognition	Revenue Recognition Sales of Neonorm Calf and Foal to distributors are made under agreements that may provide distributor price adjustments and rights of return under certain circumstances. Until the Company develops sufficient sales history and pipeline visibility, revenue and costs of distributor sales will be deferred until products are sold by the distributor to the distributor's customers. Revenue recognition depends on notification either directly from the distributor that product has been sold to the distributor's customer, when the Company has access to the data. Deferred revenue on shipments to distributors reflect the estimated effects of distributor price adjustments, if any, and the estimated amount of gross margin expected to be realized when the distributor sells through product purchased from the Company. Company sales to distributors are invoiced and included in accounts receivable and deferred revenue upon shipment. Inventory is relieved and revenue recognized upon shipment by the distributor to their customer. The Company had Neonorm revenues of $141,523 and $258,381 for the years ended December 31, 2016, and 2015.
Stock-Based Compensation	Stock-Based Compensation The Company's 2013 Equity Incentive Plan and 2014 Stock Incentive Plan (see Note 10) provides for the grant of stock options, restricted stock and restricted stock unit awards. The Company measures stock awards granted to employees and directors at fair value on the date of grant and recognizes the corresponding compensation expense of the awards, net of estimated forfeitures, over the requisite service periods, which correspond to the vesting periods of the awards. The Company issues stock awards with only service-based vesting conditions, and records compensation expense for these awards using the straight-line method. The Company uses the grant date fair market value of its common stock to value both employee and non-employee options when granted. The Company revalues non-employee options each reporting period using the fair market value of the Company's common stock as of the last day of each reporting period.
Classification of Securities	Classification of Securities The Company applies the principles of ASC 480-10 "Distinguishing Liabilities from Equity" and ASC 815-40 "Derivatives and Hedging—Contracts in Entity's Own Equity" to determine whether financial instruments such as warrants, contingently issuable shares and shares subject to repurchase should be classified as liabilities or equity and whether beneficial conversion features exist. Financial instruments such as warrants that are evaluated to be classified as liabilities are fair valued upon issuance and are remeasured at fair value at subsequent reporting periods with the resulting change in fair value recorded in other income/(expense). The fair value of warrants is estimated using the Black Scholes Merton model and requires the input of subjective assumptions including expected stock price volatility and expected life.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company's tax returns. Deferred taxes are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate, as well as the related net interest and penalties.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as changes in stockholders' equity (deficit) exclusive of transactions with owners (such as capital contributions and distributions). For the years ended December 31, 2016 and 2015 there was no difference between net loss and comprehensive loss.
Segment Data	Segment Data The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions. The Company is an animal health company focused on developing and commercializing prescription and non-prescription products for companion and production animals.
Basic and Diluted Net Loss Per Common Share	Basic and Diluted Net Loss Per Common Share Basic net loss per common share is computed by dividing net loss attributable to common stockholders for the period by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders for the period by the weighted-average number of common shares, including potential dilutive shares of common stock assuming the dilutive effect of potential dilutive securities. For periods in which the Company reports a net loss, diluted net loss per common share is the same as basic net loss per common share, because their impact would be anti-dilutive to the calculation of net loss per common share. Diluted net loss per common share is the same as basic net loss per common share for the years ended December 31, 2016 and 2015.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In November 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update No. 2016-18, Statement of Cash Flows: Restricted Cash, or ASU 2016-18, that will require entities to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. When cash, cash equivalents, restricted cash and restricted cash equivalents are presented in more than one line item on the balance sheet, the new guidance requires a reconciliation of the totals in the statement of cash flows to the related captions in the balance sheet. This reconciliation can be presented either on the face of the statement of cash flows or in the notes to the financial statements. Entities will also have to disclose the nature of their restricted cash and restricted cash equivalent balances. ASU 2016-18 becomes effective for fiscal years beginning after December 15, 2017, and interim periods within those years, with early adoption permitted. Any adjustments must be reflected as of the beginning of the fiscal year that includes that interim period. The adoption of this standard is not expected to have an impact on the Company's financial position or results of operations. In August 2016, the FASB issued Accounting Standards Update, or ASU, No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, which addresses the following cash flow issues: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. The amendments in this ASU are effective for public business entities for fiscal years beginning after December 15, 2017 and interim periods within those fiscal years and are effective for all other entities for fiscal years beginning after December 15, 2018 and interim periods within fiscal years beginning after December 15, 2019. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of the adoption of ASU No. 2016-15 on our consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which simplifies several aspects of the accounting for employee stock-based payment transactions. The areas for simplification in ASU No. 2016-09 include the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The amendments in this ASU will be effective for annual periods beginning after December 15, 2016 and interim periods within those annual periods. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU No. 2016-09 on our consolidated financial statements. In March 2016 the FASB issued ASU No. 2016-07, Investments—Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting. This new standard eliminates the requirement that when an investment qualifies for use of the equity method as a result of an increase in the level of ownership interest or degree of influence, an adjustment must be made to the investment, results of operations and retained earnings retroactively on a step-by-step basis as if the equity method had been in effect during all previous periods that the investment has been held. T ASU 2016-07 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The Company is currently evaluating the potential effects of the adoption of this update on its financial statements. In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), which provides guidance for accounting for leases. Under ASU 2016-02, the Company will be required to recognize the assets and liabilities for the rights and obligations created by leased assets. ASU 2016-02 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is currently evaluating the impact of the adoption of ASU 2016-02 on our consolidated financial statements. In November 2015, the FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes (Topic 740), which simplifies the presentation of deferred income taxes. Under ASU 2015-17, deferred tax assets and liabilities are required to be classified as noncurrent, eliminating the prior requirement to separate deferred tax assets and liabilities into current and noncurrent. The new guidance is effective for the Company beginning on January 1, 2017, with early adoption permitted. The standard may be adopted prospectively or retrospectively to all periods presented. The Company elected to early adopt the standard on a retrospective basis effective December 31, 2015, and all deferred tax assets and liabilities are classified as non-current on our balance sheet. Adoption had no effect on the Company's balance sheet for 2016 and 2015 as presented. In April 2015, the FASB issued ASU No. 2015-03, Interest—Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs, to simplify the presentation of debt issuance costs by requiring debt issuance costs to be presented as a deduction from the corresponding debt liability. ASU 2015-03 will be effective for the Company beginning in its first quarter of 2016, however early adoption is permitted for financial statements that have not been previously issued. The guidance is to be applied retrospectively to all periods presented. The Company adopted ASU 2015-03 on December 31, 2015. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements—Going Concern (Subtopic 205-40)—Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern", which provides guidance regarding management's responsibility to assess whether substantial doubt exists regarding the ability to continue as a going concern and to provide related footnote disclosures. In connection with preparing financial statements for each annual and interim reporting period, management should evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued (or within one year after the date that the financial statements are available to be issued when applicable). This ASU is effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. The Company implemented this guidance for the annual period beginning after December 15, 2016. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In June 2014, the FASB issued ASU No. 2014-12, "Compensation—Stock Compensation (Topic 718)", which requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. The performance target should not be reflected in estimating the grant-date fair value of the award. Compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period(s) for which the requisite service has already been rendered. If the performance target becomes probable of being achieved before the end of the requisite service period, the remaining unrecognized compensation cost should be recognized prospectively over the remaining requisite service period. The total amount of compensation cost recognized during and after the requisite service period should reflect the number of awards that are expected to vest and should be adjusted to reflect those awards that ultimately vest. The requisite service period ends when the employee can cease rendering service and still be eligible to vest in the award if the performance target is achieved. This guidance is effective for annual periods (and interim periods within those annual periods) beginning after December 15, 2015. The Company implemented this guidance for all interim and annual periods beginning after December 15, 2015. The adoption of this guidance did not have an impact on the Company's financial condition, results of operations or cash flows. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers." The objective of ASU 2014-19 is to establish a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most of the existing revenue recognition guidance, including industry-specific guidance. The core principle of the new standard is that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard is effective for annual reporting periods beginning after December 15, 2018 and allows for prospective or retrospective application. The Company currently anticipates utilizing the full retrospective method of adoption allowed by the standard, in order to provide for comparative results in all periods presented, and plans to adopt the standard as of January 1, 2018. The Company is currently evaluating the new guidance, however it does not believe the impact will be significant.

Balance Sheet Components (Tables)

12 Months Ended

Dec. 31, 2016

Balance Sheet Components

Schedule of property and equipment

	December 31, 2016			December 31, 2015
Lab equipment	$	811,087		$	811,087
Clinical equipment		64,870			23,300
Software		62,637			—

Total property and equipment at cost		938,594			834,387
Accumulated Depreciation		(52,649	)		(5,155	)

Property and Equipment, net	$	885,945		$	829,232

Schedule of depreciation expense

	Years Ended December 31,
	2016		2015
Depreciation—Lab Equipment—research and developoment expense	$	26,271	$	4,378
Depreciation—Clinical Equipment—research and development expense		10,203		777
Depreciation—Software—general and administrative expense		11,020		—

Total Depreciation Expense	$	47,494	$	5,155

Schedule of accrued expenses

	December 31, 2016		December 31, 2015
Accrued compensation and related:
Accrued vacation	$	223,769		187,734
Accrued payroll		2,692		80,692
Accrued payroll tax		20,140		43,702

		246,601		312,128
Accrued interest		123,982		127,149
Accrued contract manufacturing costs		—		110,141
Accrued clinical		36,725		166,750
Accrued other		175,214		82,266

Total	$	582,522		798,434

Debt and Warrants (Tables)

12 Months Ended

Dec. 31, 2016

Schedule of net long-term debt obligation

	December 31, 2016			December 31, 2015
Debt and unpaid accrued end-of-term payment	$	3,894,320		$	6,115,797
Unamortized note discount		(42,493	)		(106,635	)
Unamortized debt issuance costs		(114,626	)		(206,235	)

Net debt obligation	$	3,737,201		$	5,802,927


Current portion of long-term debt	$	1,919,675		$	1,707,899
Long-term debt, net of discount		1,817,526		$	4,095,028

Total	$	3,737,201		$	5,802,927

Schedule of future principal payments under the longterm debt

Years ending December 31	Amount
2017	$	2,032,048
2018		1,479,246

Total future principal payments		3,511,294
2018 end-of-term payment		560,000

		4,071,294
Less: unaccreted end-of-term payment at December 31, 2016		(176,974	)

Debt and unpaid accrued end-of-term payment	$	3,894,320

Schedule of interest expense on long-term debt

	December 31, 2016		December 31, 2015
Nominal Interest	$	457,448	$	224,400
Amortization of debt discount		64,142		27,798
Accretion of end-of-term payment		267,230		115,797
Debt issuance costs		178,713		43,789

	$	967,533	$	411,784

Summary of warrant activity

	December 31, 2016			December 31, 2015
Beginning balance at January 1		748,872			494,267
Warrants granted		5,253,337			254,605
Warrants cancelled		(33,333	)		—

Ending balance at December 31		5,968,876			748,872

Convertible notes payable

Schedule of interest expense on the convertible notes

	Years Ended December 31,
	2016		2015
Nominal Interest	$	18,049	$	70,619
Amortization of debt discount		—		1,925,326

	$	18,049	$	1,995,945

Schedule of interest payable on the convertible notes

	December 31, 2016		December 31, 2015
Interest Payable:	$	94,048	$	75,999

Standby bridge financing agreement

Schedule of interest expense on the convertible notes

	Years Ended December 31,
	2016		2015
Nominal Interest	$	—	$	100,000
Amortization of debt discount		—		521,291
Repayment premium		—		201,600
Debt issuance costs		—		86,667

	$	—	$	909,558

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Stock Incentive Plans (Tables)

12 Months Ended

Dec. 31, 2016

Summary of incentive plan activity

	Shares Available for Grant			Stock Options Outstanding			RSUs Outstanding			Weighted Average Stock Option Exercise Price		Weighted Average Remaining Contractual Life (Years)		Aggregate Intrinsic Value
2013 Equity Incentive Plan Balance—December 31, 2014		119,077			659,554			68,902		$	2.67
Additional shares authorized		—
Options granted		(176,364	)		176,364			—		$	7.00
Options cancelled		95,784			(95,784	)		—		$	2.53
Options available for grant cancelled upon IPO		(51,863	)		—
Options cancelled post-IPO not rolled back into the 2013 Plan		—			(42,128	)
Options exercised		—			(5,000	)		—		$	2.53
RSUs granted		(1,484	)		—			1,484
RSUs cancelled		14,850			—			(14,850	)

2013 Equity Incentive Plan Balance—December 31, 2015		—			693,006			55,536		$	3.74
2014 Stock Stock Plan Balance—December 31, 2014		—
Shares authorized		333,333
Options granted		(241,500	)		241,500					$	4.32
Options cancelled		15,000			(15,000	)				$	5.09

Combined Incentive Plan Balance—December 31, 2015		106,833			919,506			55,536		$	3.87		8.81	$	—
2013 Equity Incentive Plan Activity:
Options cancelled not rolled back into the 2013 Plan					(127,629	)				$	4.19
RSUs vested and released								(27,768	)
RSUs cancelled								(6,979	)
2014 Stock Incentive Plan Activity:
Additional shares authorized		1,712,498
Options granted		(1,927,121	)		1,927,121					$	1.97
Options cancelled		147,778			(147,778	)				$	2.28

Combined Incentive Plan Balance—December 31, 2016		39,988			2,571,220			20,789		$	2.52		8.77


Options vested and exercisable—December 31, 2016					983,147					$	3.41		8.25	$	—


Options vested and expected to vest—December 31, 2016					2,163,246					$	2.52		8.73	$	—

Summary of stock-based compensation expense

	Years Ended December 31,
	2016		2015
Research and development expense	$	181,489	$	472,145
Sales and marketing expense		73,679		54,115
General and administrative expense		462,759		465,905

Total	$	717,927	$	992,165

Employee stock options

Schedule of estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model

	Years Ended December 31,
	2016	2015
Weighted-average volatility	66.25 - 72.08%	55.43 - 61.51%
Weighted-average expected term (years)	5.00 - 5.82	5.15 - 5.82
Risk-free interest rate	1.10 - 2.15%	1.60 - 1.84%
Expected dividend yield	—	—

Non-employee stock options

Schedule of estimated grant-date fair value of stock options calculated using the Black-Scholes option-pricing model

	Years Ended December 31,
	2016	2015
Weighted-average volatility	78.30 - 80.04%		76.63	%
Weighted-average expected term (years)	9.19 - 10.00		9.69
Risk-free interest rate	1.32 - 2.46%		2.25	%
Expected dividend yield	—		—

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2016

Income Taxes

Schedule of components of the provision for income taxes

	December 31, 2016			December 31, 2015
Current:
Federal	$	—		$	—
State		—			—
Foreign		—			—

Total Current		—			—

Deferred:
Federal		(4,387,544	)		(4,197,007	)
State		(1,249,149	)		(587,696	)
Foreign		—			—

Total Deferred		(5,636,693	)		(4,784,703	)
Valuation Allowance		5,636,693			4,784,703

Total Provision for Income Taxes	$	—		$	—

Schedule of effective tax rate, differed from the federal statutory rate

	December 31, 2016			December 31, 2015
Statutory Rate		(34.0	)%		(34.0	)%
State Taxes		(5.6	)%		(3.6	)%
Tax Credits		(0.5	)%		5.2	%
Other		1.8	%		1.7	%
Valuation Allowance		38.3	%		30.7	%

Effective Tax Rate		0.0	%		0.0	%

Schedule of net deferred tax assets

	December 31, 2016			December 31, 2015
Non-current Deferred Tax Assets:
Net Operating Costs	$	9,626,610		$	7,459,489
Tax Credits		374,605			261,851
Stock Compensation		297,438			188,602
Fixed Assets and Intangibles		3,700,557			470,577
Other		93,434			75,432

		14,092,644			8,455,951
Valuation Allowance		(14,092,644	)		(8,455,951	)

Net Non-current Deferred Tax Assets	$	—		$	—

Schedule of reconciliation of the beginning and ending amounts of unrecognized tax benefits

	December 31, 2016		December 31, 2015
Gross Unrecognized Tax Benefit—Beginning Balance	$	78,930	$	31,006
Increases Related to Tax Positions from Prior Years		—		5,920
Increases Related to Tax Positions Taken During t the Current Year		34,143		42,004

Gross Unrecognized Tax Benefit—Beginning Balance	$	113,073	$	78,930

Organization and Business (Details)					1 Months Ended				12 Months Ended
Organization and Business (Details)	Oct. 06, 2016 company	May 18, 2015 USD ($) $ / shares shares	Oct. 27, 2014 shares	Jun. 11, 2013 shares	Oct. 31, 2016 USD ($) shares	Jun. 30, 2016 USD ($) shares	Feb. 29, 2016 USD ($) $ / shares shares	Oct. 31, 2014	Dec. 31, 2016 USD ($) segment $ / shares shares	Dec. 31, 2015 USD ($) shares	Oct. 26, 2014 shares
Number of segments \| segment									1
Number of companies to merge under letter of intent (LOI) \| company	2
Reverse Stock Split
Common stock, shares authorized \| shares									50,000,000	50,000,000
Initial Public Offering and Secondary Public Offering
Net proceeds from initial public offering \| $										$ 18,810,484
Liquidity
Accumulated deficit \| $									$ (40,436,108)	$ (25,702,328)
IPO
Initial Public Offering and Secondary Public Offering
Offering expenses \| $		$ 2,900,000
Non-cash offering expenses \| $		3,300,000
Underwriters' over-allotment option
Initial Public Offering and Secondary Public Offering
Offering expenses \| $		$ 1,200,000
Private investment
Initial Public Offering and Secondary Public Offering
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares) \| shares									2,027,490
Liquidity
Shares issued (in shares) \| shares									2,027,490
Proceeds from issuance of common stock \| $									$ 2,676,700
Maximum number of shares company is permitted to issue \| shares									2,027,490
Share price required to issue shares more than permitted number (in dollars per share) \| $ / shares									$ 1.32
Common Stock
Reverse Stock Split
Reverse stock split ratio			0.667					0.667
Common stock, shares authorized \| shares			15,000,000								10,000,000
Initial Public Offering and Secondary Public Offering
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares) \| shares										2,860,000
Liquidity
Shares issued (in shares) \| shares										2,860,000
Common Stock \| IPO
Initial Public Offering and Secondary Public Offering
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares) \| shares		2,860,000
Shares issued (price per share) \| $ / shares		$ 7.00
Net proceeds from initial public offering \| $		$ 15,900,000
Underwriting discounts and commissions \| $										$ 1,209,802
Offering expenses \| $										$ 2,897,825
Issuance of common stock upon conversion (in shares) \| shares		2,010,596
Liquidity
Shares issued (in shares) \| shares		2,860,000
Common Stock \| Secondary public offering
Initial Public Offering and Secondary Public Offering
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares) \| shares							2,000,000
Shares issued (price per share) \| $ / shares							$ 2.50
Net proceeds from initial public offering \| $							$ 4,100,000
Underwriting discounts and commissions \| $							373,011
Offering expenses \| $							$ 496,887
Liquidity
Shares issued (in shares) \| shares							2,000,000
Common Stock \| Private investment
Initial Public Offering and Secondary Public Offering
Issuance of common stock in initial public offering, net of discounts and commissions of $1,209,802, offering costs of $2,897,825 and offering costs in the form of common stock warrants of $400,400 (in shares) \| shares					170,455	222,222			1,348,601
Offering expenses \| $						$ 105,398
Liquidity
Term of stock purchase agreement						30 months
Shares issued (in shares) \| shares					170,455	222,222			1,348,601
Proceeds from issuance of common stock \| $					$ 150,000	$ 394,534			$ 2,176,700
Common Stock \| Private investment \| Maximum
Liquidity
Value of common stock that may be sold to a private investor \| $						$ 15,000,000
Service Agreement \| Napo
Number of shares issued in exchange for cash and services \| shares				2,666,666

Related Party Transactions - Royalty payable to former parent and license fee payable to former parent and related agreement (Details) - USD ($)	1 Months Ended			12 Months Ended
	Jan. 31, 2015	Jan. 31, 2014	Jul. 31, 2013	Dec. 31, 2016	Dec. 31, 2015
License agreement
Property and equipment, net				$ 885,945	$ 829,232
Option Agreement \| Napo
License agreement
License fees paid			$ 100,000
Term of agreement			2 years
License Agreement \| Napo
License agreement
License fees paid				425,000	1,200,000
Payment obligation of one-time non-refundable license fee	$ 1,750,000	$ 2,000,000
Option fee		100,000
Milestone payments due		$ 3,150,000
Royalty expiration term from the first sale of each individual product		10 years
Minimum proceeds from IPO prior to December 31, 2015, required for royalty reduction		$ 10,000,000
Milestone payments due in the event of minimum proceeds from IPO		$ 0
Unpaid royalties				171
License Agreement \| Napo \| Products derived from Croton Lechleri
License agreement
Royalty rate for net sales below revenue base (as a percent)		8.00%
Net product sales upon which royalty rate increases		$ 30,000,000
Royalty rate for net sales above revenue base (as a percent)		10.00%
Royalties payments due in the event of minimum proceeds from IPO		$ 0
License Agreement \| Napo \| Prescription products derived from Croton Lechleri
License agreement
Royalty rate in the event of an IPO in excess of a specified amount		2.00%
License Agreement \| Napo \| Nonprescription products derived from Croton Lechleri
License agreement
Royalty rate in the event of an IPO in excess of a specified amount		1.00%
License Agreement \| Napo \| Pharmaceutical prescription products not derived from Croton Lechleri
License agreement
Royalty on annual net sales of products (as a percent)		2.00%
License Agreement \| Napo \| Nonprescription products not derived from Croton Lechleri
License agreement
Royalty on annual net sales of products (as a percent)		1.00%
License Agreement \| Napo \| Accrued Liabilities
License agreement
Unpaid royalties					2,810
License Agreement \| Napo \| Property and equipment
License agreement
Property and equipment, net				811,087
License Agreement \| Napo \| General and administrative expense
License agreement
Royalties incurred				1,015	$ 39,734
License Agreement \| Napo \| Research and development expense
License agreement
Property and equipment, net				$ 1,200,000

Commitments and Contingencies - Contract Manufacturing Commitment (Details)					1 Months Ended	12 Months Ended
	Jul. 15, 2016 EUR (€)	Mar. 29, 2016 EUR (€)	Dec. 31, 2015 EUR (€) shares	Jun. 26, 2014 EUR (€) item shares	May 31, 2015 EUR (€)	Dec. 31, 2016 EUR (€) shares item	Dec. 31, 2016 USD ($) item	Dec. 31, 2015 USD ($)	Nov. 08, 2016 $ / shares	Mar. 31, 2016 EUR (€)	Jun. 30, 2015 EUR (€)	Mar. 31, 2015 $ / shares	Mar. 31, 2015 EUR (€)	Mar. 25, 2015 EUR (€)	Oct. 30, 2014
Commitments and Contingencies
Number of warrants issued to purchase shares of common stock (in shares) \| shares			26,785			67,655
Exercise price as a percentage of initial public offering price															80.00%
Exercise price (in dollars per share) \| $ / shares									$ 0.01
Accrued liabilities
Commitments and Contingencies
Contract amortization costs included in accrued liabilities \| $							$ 0	$ 110,141
Transfer Agreement \| Manufacturer
Commitments and Contingencies
Prepayment of start-up fee				€ 500,000	€ 500,000	€ 500,000
Prepayment of start-up fee which is to be paid at the earlier to occur of September 15, 2014 or the closing date of an initial public offering				250,000
Prepayment of start-up fee which is to be paid at the time of installation and qualification of the Company's equipment				250,000
Prepayment related to technology transfer				620,000	215,000
Prepayment related to technology transfer which is to be paid within five days of the signature of the Transfer Agreement				310,000
Prepayment related to technology transfer which is to be paid after the delivery of a final study report				310,000
Prepayment for design of a portion of the Manufacturer's facility which is to be paid within five days of the signature of the Transfer Agreement				€ 100,000
Period within which prepayment for design of a portion of the Manufacturer's facility is payable from signature of the Transfer Agreement				5 days
Bonus fee payable			€ 150,000.00	€ 300,000
Number of installments \| item				2
Bonus fee paid	€ 150,000		150,000		€ 150,000	€ 150,000
Aggregate amount payable to Manufacturer upon the delivery of agreed-upon levels of satisfactory product pursuant to the agreement			€ 250,000	€ 500,000						€ 250,000			€ 250,000
Number of warrants issued to purchase shares of common stock (in shares) \| shares				16,666
Exercise price as a percentage of initial public offering price				90.00%
Exercise price (in dollars per share) \| $ / shares												$ 6.30
Remaining balance due related to prepayment of technology transfer														€ 310,000
Increase in prepayment for design of portion of manufacturer facility payable within specified days of signature of agreement														170,000
Transfer Agreement \| API
Commitments and Contingencies
Amount of product supplied at no cost (in Kg) \| item						400	400
Payments made		€ 250,000
Amendment to Transfer Agreement first portion due \| Manufacturer
Commitments and Contingencies
Prepayment related to technology transfer														€ 215,000
Payments related to design of a portion of manufacturing facility						€ 150,000
Amendment to Transfer Agreement second portion due \| Manufacturer
Commitments and Contingencies
Prepayment related to technology transfer											€ 95,000
Payments related to design of a portion of manufacturing facility						€ 20,000

Debt and Warrants - Debt (Details)															1 Months Ended								2 Months Ended	3 Months Ended	12 Months Ended
Debt and Warrants - Debt (Details)	Aug. 01, 2018 USD ($)	Dec. 31, 2016 USD ($) $ / shares shares	Nov. 08, 2016 $ / shares shares	Apr. 21, 2016 USD ($)	Aug. 18, 2015 USD ($)	Aug. 15, 2015 USD ($)	Jun. 02, 2015 shares	Dec. 23, 2014 USD ($) item $ / shares shares	Dec. 03, 2014 USD ($) $ / shares	Oct. 30, 2014 USD ($) item shares	Jul. 16, 2014 USD ($) $ / shares shares	Jun. 26, 2014 USD ($) $ / shares shares	Jun. 26, 2014 USD ($) $ / shares shares	Jun. 02, 2014 USD ($) item $ / shares	Nov. 30, 2016 $ / shares	Aug. 31, 2015 USD ($)	May 31, 2015 USD ($) shares	Apr. 30, 2015 $ / shares shares	Mar. 31, 2015 USD ($) $ / shares	Feb. 28, 2015 USD ($) item $ / shares shares	Aug. 31, 2014 USD ($) $ / shares shares	Feb. 28, 2014 USD ($) shares	Feb. 28, 2014 USD ($)	Sep. 30, 2013 USD ($) item shares	Dec. 31, 2016 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) shares	Jan. 31, 2017 USD ($)	Sep. 30, 2016 $ / shares	Jul. 31, 2016 USD ($)	Mar. 01, 2016	Jan. 31, 2016 $ / shares shares	Dec. 22, 2015 USD ($)	Jun. 30, 2015 $ / shares
Debt and Warrants
Gross aggregate proceeds																										$ 1,250,000
Interest rate (as a percent)																													12.00%
Number of shares issued for notes converted \| shares																	178,571
Interest expense																									$ 985,549	3,317,287
Amortization of debt discount																										$ 521,291
Number of warrants issued to purchase shares of common stock (in shares) \| shares		67,655																							67,655	26,785
Exercise price (in dollars per share) \| $ / shares			$ 0.01
Loss on extinguishment of debt																									$ 108,000
Notes payable														$ 300,000
Interest payable on long-term debt		$ 33,929																							$ 33,929	$ 15,880
Exercise price as a percentage of initial public offering price										80.00%
Term		5 years 4 months 28 days	5 years 8 months 19 days												5 years 6 months
Fair value of warrants																					$ 114,300
Strike price (in dollars per share) \| $ / shares		$ 0.716	$ 0.91												$ 0.69										$ 0.716
Volatility (as a percent)		73.62%	70.35%												71.92%
Dividend yield (as a percent)		0.00%	0.00%												0.00%
Risk-free interest rate (as a percent)		2.00%	1.45%												1.87%
Interest Paid																									$ 478,665	173,250
Stand-by line of credit					$ 8.0
Initial loan commitment					6.0
Proceeds required to be maintained in cash					$ 4,500,000																					3,000,000						$ 3,000,000
Repayment of loan from restricted cash																									2,500,000
Short-term debt
Notes payable														$ 300,000
Net debt obligation		$ 150,000																							150,000	150,000
Nominal interest																										100,000
Amortization of debt discount																										521,291
Repayment premium																										201,600
Debt issuance costs																										86,667
Total																										909,558
Interest payable on convertible notes payable		123,982																							123,982	127,149
Long-term debt
Debt and unpaid accrued end-of-term payment																													$ 150,000
Current portion of long-term debt		1,919,675																							1,919,675	1,707,899
Long-term debt, net of discount		1,817,526																							1,817,526	4,095,028
Nominal interest																										100,000
Amortization of debt discount																										521,291
Debt Issuance Cost																										86,667
Total																										909,558
Investor [Member]
Debt and Warrants
Interest expense																									17,753	15,880
Interest payable on long-term debt		17,753																							17,753	17,753
Transfer Agreement \| Manufacturer
Debt and Warrants
Number of warrants issued to purchase shares of common stock (in shares) \| shares												16,666	16,666
Exercise price (in dollars per share) \| $ / shares																			$ 6.30
Exercise price as a percentage of initial public offering price												90.00%	90.00%
Warrants to purchase common stock \| Transfer Agreement \| Manufacturer
Debt and Warrants
Exercise price (in dollars per share) \| $ / shares																			$ 6.30
Term												5 years
Warrants to purchase common stock \| Common Stock \| Transfer Agreement \| Manufacturer
Debt and Warrants
Number of warrants issued to purchase shares of common stock (in shares) \| shares												16,666	16,666
Exercise price (in dollars per share) \| $ / shares												$ 4.35	$ 4.35
Exercise price as a percentage of initial public offering price												90.00%	90.00%
Term													5 years
Fair value of warrants												$ 37,840	$ 37,840
Strike price (in dollars per share) \| $ / shares												$ 4.83	$ 4.83
Volatility (as a percent)												49.00%
Dividend yield (as a percent)												0.00%
Risk-free interest rate (as a percent)												1.64%
Standby bridge financing agreement
Debt and Warrants
Number of warrants issued to purchase shares of common stock (in shares) \| shares										178,569
Exercise price (in dollars per share) \| $ / shares									$ 5.23
Term									5 years
Fair value of warrants									$ 505,348
Strike price (in dollars per share) \| $ / shares									$ 5.01
Volatility (as a percent)									63.00%
Dividend yield (as a percent)									0.00%
Risk-free interest rate (as a percent)									1.61%
Unamortized note discount										$ 605,348
Number of lenders \| item										2
Aggregate principal amount of bridge financing									$ 1,000,000
Interest Paid																	$ 1,321,600
Value to be divided by IPO exercise price to determine number of warrants granted																			$ 1,000,000
Short-term debt
Unamortized note discount										$ (605,348)
Long-term debt
Unamortized note discount										$ (605,348)
Standby bridge financing agreement \| IPO
Debt and Warrants
Exercise price (in dollars per share) \| $ / shares																			$ 5.60
Standby bridge financing agreement \| Interest Expense.
Debt and Warrants
Amortization of debt discount																									521,291
Term										6 months
Unamortized note discount										$ 100,000
Additional financing costs		86,667								104,000															86,667
Short-term debt
Unamortized note discount										(100,000)
Amortization of debt discount																									521,291
Debt issuance costs										104,000
Long-term debt
Unamortized note discount										(100,000)
Amortization of debt discount																									521,291
Debt Issuance Cost										$ 104,000
Convertible notes payable
Debt and Warrants
Interest expense																									18,049	15,880
Notes payable		18,049																							18,049	70,619
Unamortized note discount																										(1,925,326)
Short-term debt
Notes payable		18,049																							18,049	70,619
Unamortized note discount																										1,925,326
Net debt obligation		18,049																							18,049	1,995,945
Nominal interest																									94,048	75,999
Long-term debt
Debt and unpaid accrued end-of-term payment		150,000																							150,000	150,000
Unamortized note discount																										1,925,326
Nominal interest																									94,048	75,999
Convertible promissory notes
Debt and Warrants
Number of convertible promissory notes issued \| item																				2				4
Gross aggregate proceeds																								$ 525,000
Interest rate (as a percent)																								8.00%
Number of business days after the date of consummation of the initial closing of a first equity round of financing, when the debt instrument is due																								10 days
Pre-money valuation threshold amount																								$ 3,000,000
Number of shares issued for notes converted \| shares																						207,664
Amortization of debt discount																						$ 4,071	$ 1,443
Number of warrants issued to purchase shares of common stock (in shares) \| shares																				22,320
Exercise price (in dollars per share) \| $ / shares																				$ 5.60
Notes payable																				$ 250,000
Principal and interest paid on debt																	103,912
Retirement of convertible promissory notes																	$ 100,000
Short-term debt
Notes payable																				$ 250,000
Amortization of debt discount																						4,071	1,443
Long-term debt
Amortization of debt discount																						$ 4,071	$ 1,443
Convertible promissory notes \| Interest Expense.
Debt and Warrants
Interest expense																									0	250,000
Amortization of debt discount																									1,000,000
Short-term debt
Amortization of debt discount																									1,000,000
Long-term debt
Amortization of debt discount																									1,000,000
Convertible promissory notes \| Investor [Member]
Debt and Warrants
Interest rate (as a percent)																		12.00%
Number of warrants issued to purchase shares of common stock (in shares) \| shares																		89,285
Exercise price (in dollars per share) \| $ / shares																		$ 5.60
Notes payable																			$ 1,000,000
Investment Warrants Expiration Date																		Dec. 31, 2017
Short-term debt
Notes payable																			$ 1,000,000
Convertible promissory notes \| Warrants to purchase common stock \| Common Stock
Debt and Warrants
Exercise price as a percentage of purchase price paid by equity investors when pre-money valuation threshold amount is achieved																								75.00%
Number of warrants issued to purchase shares of common stock (in shares) \| shares																								207,664
Exercise price (in dollars per share) \| $ / shares																												$ 2.53
Warrant term																								5 years
Convertible promissory notes issued June 2, 2014
Debt and Warrants
Interest rate (as a percent)														3.00%
Number of shares issued for notes converted \| shares							53,571
Interest expense																										3,237
Exercise price (in dollars per share) \| $ / shares														$ 5.60
Interest payable on long-term debt																										8,507
Number of accredited investors \| item														2
Aggregate principal amount issued to board member to which Series A preferred stock was sold														$ 200,000
Beneficial conversion feature														75,000
Convertible promissory note issued July 16, 2014
Debt and Warrants
Interest rate (as a percent)											3.00%
Number of shares issued for notes converted \| shares											26,785
Interest expense																										1,627
Exercise price (in dollars per share) \| $ / shares											$ 5.60
Notes payable											$ 150,000
Interest payable on long-term debt																										3,711
Beneficial conversion feature											37,500
Short-term debt
Notes payable											$ 150,000
Convertible promissory note issued July 16, 2014 \| Interest Expense.
Debt and Warrants
Amortization of debt discount																										17,857
Short-term debt
Amortization of debt discount																										17,857
Long-term debt
Amortization of debt discount																										17,857
Convertible note purchase agreement
Debt and Warrants
Gross aggregate proceeds								$ 650,000
Interest rate (as a percent)								12.00%
Interest expense																										28,210
Amortization of debt discount																										141,890
Number of warrants issued to purchase shares of common stock (in shares) \| shares								58,035
Exercise price (in dollars per share) \| $ / shares								$ 4.15											$ 5.60														$ 5.60
Interest payable on long-term debt																										30,132
Number of accredited investors \| item								3
Aggregate principal amount issued to board member to which Series A preferred stock was sold								$ 250,000						$ 200,000
Beneficial conversion feature																										502,057
Term								3 years
Fair value of warrants								$ 147,943
Strike price (in dollars per share) \| $ / shares								$ 4.59
Volatility (as a percent)								49.00%
Dividend yield (as a percent)								0.00%
Risk-free interest rate (as a percent)								1.10%
Short-term debt
Amortization of debt discount																										141,890
Long-term debt
Amortization of debt discount																										141,890
Convertible note purchase agreement \| IPO
Debt and Warrants
Number of shares issued for notes converted \| shares								116,070
Exercise price as a percentage of initial public offering price								80.00%			5.60%
Strike price (in dollars per share) \| $ / shares																		$ 5.60
Convertible note purchase agreement \| Interest Expense.
Debt and Warrants
Amortization of debt discount																										31,250
Beneficial conversion feature																										484,329
Short-term debt
Amortization of debt discount																										31,250
Long-term debt
Amortization of debt discount																										31,250
Line of credit and loan agreement
Debt and Warrants
Number of warrants issued to purchase shares of common stock (in shares) \| shares																					33,333
Exercise price (in dollars per share) \| $ / shares																			$ 5.60		$ 6.40
Exercise price as a percentage of initial public offering price																					80.00%
Term																					2 years
Strike price (in dollars per share) \| $ / shares																					$ 8.00
Volatility (as a percent)																					52.00%
Dividend yield (as a percent)																					0.00%
Risk-free interest rate (as a percent)																					0.52%
Drawdown amount																			$ 0
Line of credit and loan agreement \| Maximum
Debt and Warrants
Stand-by line of credit																					$ 1,000,000
Loan and security agreement
Debt and Warrants
Interest rate (as a percent)																														9.90%
Amortization of debt discount																									64,142	27,798
Unamortized note discount		42,493														$ 134,433									42,493	106,635
Stand-by line of credit																8,000,000
Initial loan commitment																6,000,000
Proceeds required to be maintained in cash																$ 4,500,000
Additional borrowing capacity contingent on achievement of milestones						$ 2,000,000
Term of agreement																3 years
Effective interest rate																15.00%
Prior notification period required for pre-payment of principal and accrued interest (in days)																5 days
Repayment of loan from restricted cash				$ 1,500,000
Short-term debt
Unamortized note discount		(42,493)														$ (134,433)									(42,493)	(106,635)
Nominal interest																									457,448	224,400
Amortization of debt discount																									64,142	27,798
Deferred financing costs																									178,713	43,789
Total																									967,533	411,784
Future principal payments of debt
2017		2,032,048																							2,032,048
2018		1,479,246																							1,479,246
Total future principal payments		3,511,294																							3,511,294
2018 end-of-term-payment		560,000																							560,000
Total		4,071,294																							4,071,294
Less: unaccreted end-of-term payment at December 31, 2016		(176,974)																							(176,974)
Debt and unpaid accrued end-of-term payment		3,894,320																							3,894,320
Long-term debt
Debt and unpaid accrued end-of-term payment		3,894,320																							3,894,320	6,115,797
Unamortized note discount		(42,493)														$ (134,433)									(42,493)	(106,635)
Unamortized debt issuance costs		(114,626)																							(114,626)	(206,235)
Total		3,737,201																							3,737,201	5,802,927
Current portion of long-term debt		1,919,675																							1,919,675	1,707,899
Long-term debt, net of discount		$ 1,817,526																							1,817,526	4,095,028
End-of-term payment																										560,000
Nominal interest																									457,448	224,400
Amortization of debt discount																									64,142	27,798
Accretion of end-of-term payment																									267,230	115,797
Total																									$ 967,533	$ 411,784
Loan and security agreement \| Forecast
Debt and Warrants
Balloon amount payable on August 1, 2018	$ 560,000
Loan and security agreement \| Prepayment during the first twelve months member
Debt and Warrants
Prepayment charge during first twelve months of loan when a minimum cash balance is required as a percent of minimum cash balance																2.00%
Prepayment charge during first twelve months of loan when a minimum cash balance is required as a percent of difference between amount being prepaid and minimum cash balance																3.00%
Prepayment charge during first twelve months of loan when no minimum cash balance is required as a percent of amount being prepaid																3.00%
Loan and security agreement \| Prepayment after the first twelve months member
Debt and Warrants
Prepayment charge as a percent of amount being prepaid																1.00%
Convertible promissory note issued to Serious Change II LP
Debt and Warrants
Number of warrants issued to purchase shares of common stock (in shares) \| shares			120,000																												370,916
Strike price (in dollars per share) \| $ / shares																															$ 0.51
Convertible promissory note issued to Serious Change II LP \| Subsequent events
Debt and Warrants
Notes payable																											$ 150,000
Short-term debt
Notes payable																											$ 150,000

Stockholders' Equity (Details)				1 Months Ended				12 Months Ended
Stockholders' Equity (Details)	Dec. 31, 2016 USD ($) $ / shares shares	Nov. 22, 2016 USD ($) $ / shares shares	Nov. 08, 2016 $ / shares	Nov. 30, 2016 $ / shares	Oct. 31, 2016 USD ($) shares	Jun. 30, 2016 USD ($) $ / shares shares	Feb. 29, 2016 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) item $ / shares shares	Dec. 31, 2015 USD ($) $ / shares shares	Nov. 29, 2016 USD ($)	Oct. 27, 2014 shares	Oct. 26, 2014 shares
Stockholders' Equity
Common stock, shares authorized \| shares	50,000,000							50,000,000	50,000,000
Common stock par value (in dollars per share) \| $ / shares	$ 0.0001							$ 0.0001	$ 0.0001
Number of voting rights entitled for each share of common stock held \| item								1
Share issue price (in dollars per share) \| $ / shares	$ 0.716		$ 0.91	$ 0.69				$ 0.716
Net proceeds from initial public offering									$ 18,810,484
Amount of shares issued									$ 15,512,260
Number of warrants issued to purchase shares of common stock (in shares) \| shares	67,655							67,655	26,785
Strike price (in dollars per share) \| $ / shares			0.01
Issuance costs of equity and warrants
Total		$ 1,000,001
% Allocation		100.00%
Warrants issuance costs (allocated)		$ 225,944
Total		$ 322,777
Fair Value Assumptions and Methodology for Assets and Liabilities
Share Price \| $ / shares	$ 0.716		0.91	0.69				$ 0.716
Exercise price \| $ / shares	$ 0.75		$ 0.01	$ 0.75				$ 0.75
Term	5 years 4 months 28 days		5 years 8 months 19 days	5 years 6 months
Volatility (as a percent)	73.62%		70.35%	71.92%
Dividend yield (as a percent)	0.00%		0.00%	0.00%
Risk-free interest rate (as a percent)	2.00%		1.45%	1.87%
Preferred stock, shares authorized \| shares	10,000,000							10,000,000	10,000,000
Preferred stock, par value (in dollars per share) \| $ / shares	$ 0.0001							$ 0.0001	$ 0.0001
Preferred stock, shares issued \| shares	0							0	0
Preferred stock, shares outstanding \| shares	0							0	0
Shares of common stock reserved for issuance
Options issued and outstanding \| shares	2,571,220							2,571,220	919,506
Options available for grant \| shares	39,988							39,988	106,833
RSUs issued and outstanding \| shares	20,789							20,789	55,536
Warrants issued and outstanding \| shares	5,968,876							5,968,876	748,872
Convertible notes \| shares	67,655							67,655	26,785
Total \| shares	8,668,528							8,668,528	1,857,532
2016 Private Placement
Stockholders' Equity
Shares issued (in shares) \| shares		1,666,668
Share issue price (in dollars per share) \| $ / shares		$ 0.60
Net proceeds from issuance of common stock		$ 677,224
Amount of shares issued		1,000,000
Issuance costs of equity and warrants
Common stock issuance costs (allocated)		$ 322,777
Fair Value Assumptions and Methodology for Assets and Liabilities
Share Price \| $ / shares		$ 0.60
Private investment
Stockholders' Equity
Shares issued (in shares) \| shares								2,027,490
Share price required to issue shares more than permitted number (in dollars per share) \| $ / shares								$ 1.32
Net proceeds from issuance of common stock								$ 2,676,700
Common Stock
Stockholders' Equity
Common stock, shares authorized \| shares											15,000,000	10,000,000
Shares issued (in shares) \| shares									2,860,000
Amount of shares issued		$ 106,000							$ 286
Issuance costs of equity and warrants
Fair value of common stock		$ 156,522
% Allocation		16.00%
Common stock issuance costs (allocated)		$ 50,522
Common Stock \| Private investment
Stockholders' Equity
Term of stock purchase agreement						30 months
Shares issued (in shares) \| shares					170,455	222,222		1,348,601
Private Offering Price (in dollars per share) \| $ / shares						$ 2.25
Net proceeds from issuance of common stock					$ 150,000	$ 394,534		$ 2,176,700
Amount of shares issued						500,000
Offering expenses						$ 105,398
Shares issued to a private investor in payment of underwriting discounts and commissions \| shares						456,667
Common Stock \| Secondary public offering
Stockholders' Equity
Shares issued (in shares) \| shares							2,000,000
Shares issued (price per share) \| $ / shares							$ 2.50
Net proceeds from initial public offering							$ 4,100,000
Underwriting discounts and commissions							373,011
Offering expenses							$ 496,887
Common Stock \| Maximum \| Private investment
Stockholders' Equity
Value of common stock that may be sold to a private investor						$ 15,000,000
Series A warrants and placement agent warrants
Stockholders' Equity
Strike price (in dollars per share) \| $ / shares	$ 0.75							$ 0.75
Issuance costs of equity and warrants
Fair value of warrants		$ 56,000
Fair Value Assumptions and Methodology for Assets and Liabilities
Term	5 years 4 months 28 days	5 years 6 months
Volatility (as a percent)	73.62%	71.92%
Risk-free interest rate (as a percent)	2.00%	1.87%
Warrant liability	$ 799,201							$ 799,201
Series A Warrants
Stockholders' Equity
Number of warrants issued to purchase shares of common stock (in shares) \| shares		1,666,668
Strike price (in dollars per share) \| $ / shares		$ 0.75
Issuance costs of equity and warrants
Fair value of warrants		$ 700,001
% Allocation		70.00%
Warrants issuance costs (allocated)		$ 225,944
Fair Value Assumptions and Methodology for Assets and Liabilities
Warrant liability		$ 756,001								$ 756,001
Shares of common stock reserved for issuance
Convertible notes \| shares		1,666,668
Series B warrants
Stockholders' Equity
Number of warrants issued to purchase shares of common stock (in shares) \| shares		1,666,668
Strike price (in dollars per share) \| $ / shares		$ 0.90
Fair Value Assumptions and Methodology for Assets and Liabilities
Term		1 year
Volatility (as a percent)		116.65%
Risk-free interest rate (as a percent)		0.78%
Shares of common stock reserved for issuance
Convertible notes \| shares		1,666,668
Warrants (Series B and C)
Stockholders' Equity
Amount of shares issued		$ 97,167
Issuance costs of equity and warrants
Fair value of warrants		$ 143,478
% Allocation		14.00%
Warrants issuance costs (allocated)		$ 46,311
Series C warrants
Stockholders' Equity
Number of warrants issued to purchase shares of common stock (in shares) \| shares		1,666,668
Strike price (in dollars per share) \| $ / shares		$ 1.00
Fair Value Assumptions and Methodology for Assets and Liabilities
Term		1 year 6 months
Volatility (as a percent)		116.92%
Risk-free interest rate (as a percent)		0.94%
Shares of common stock reserved for issuance
Convertible notes \| shares		1,666,668

Stock Incentive Plans - Summary of Stock Incentive Plans (Details) - USD ($)		1 Months Ended		12 Months Ended
	May 12, 2015	Jun. 30, 2016	Jul. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2013	Apr. 30, 2014
Shares Available for Grant
Beginning balance (in shares)				106,833
Ending balance (in shares)				39,988	106,833
Stock Options Outstanding
Beginning balance (in shares)				919,506
Options Exercised (in shares)				0
Ending balance (in shares)				2,571,220	919,506
RSUs Outstanding
Beginning balance (in shares)				55,536
Ending balance (in shares)				20,789	55,536
Weighted Average Stock Option Exercise Price
Beginning balance (in dollars per share)				$ 3.87
Ending balance (in dollars per share)				$ 2.52	$ 3.87
Weighted Average Remaining Contractual Life (Years)
Weighted Average Remaining Contractual Life (Years)				8 years 9 months 7 days	8 years 9 months 22 days
Options vested, exercisable and expected to vest
Options vested and exercisable (in shares)				983,147
Options vested and exercisable (in dollars per share)				$ 3.41
Options vested and exercisable (in years)				8 years 3 months
Options vested and expected to vest (in shares)				2,163,246
Options vested and expected to vest (in dollars per share)				$ 2.52
Options vested and expected to vest (in years)				8 years 8 months 23 days
Weighted average grant date fair value of stock options granted (in dollars per share)				$ 0.86	$ 2.90
Number of options vested (in shares)				655,481	413,063
Fair value of options vested on grant date				$ 722,134	$ 893,974
Grant date fair value of options vested (in dollars per share)					$ 0.43
Intrinsic value of options exercised					$ 0
2013 Plan
Shares Available for Grant
Beginning balance (in shares)					119,077
Options available for grant cancelled upon IPO (in shares)					(51,863)
Stock Options Outstanding
Beginning balance (in shares)				693,006	659,554
Options Granted (in shares)					176,364
Options Cancelled (in shares)					(95,784)
Options Cancelled post-IPO not rolled back into the 2013 Plan (in shares)					(42,128)
Options Cancelled not rolled back into the 2013 Plan (in shares)				(127,629)
Options Exercised (in shares)					(5,000)
Ending balance (in shares)					693,006
RSUs Outstanding
Beginning balance (in shares)				55,536	68,902
RSUs Granted (in shares)				27,768	1,484
RSUs Cancelled (in shares)				(6,979)	(14,850)
Ending balance (in shares)					55,536
Weighted Average Stock Option Exercise Price
Beginning balance (in dollars per share)				$ 3.74	$ 2.67
Options Granted (in dollars per share)					7.00
Options Cancelled not rolled back into the 2013 Plan (in dollars per share)				$ 4.19
Options Cancelled (in dollars per share)					2.53
Options Exercised (in dollars per share)					2.53
Ending balance (in dollars per share)					$ 3.74
2013 Plan \| Stock options
Stock Incentive Plans
Number of shares reserved for issuance						300,000	847,533
Shares Available for Grant
Shares Authorized (in shares)						300,000	847,533
Stock Options Outstanding
Options Granted (in shares)						0
2014 Plan
Stock Incentive Plans
Number of shares reserved for issuance				1,712,498	333,333
Shares Available for Grant
Shares Authorized (in shares)				1,712,498	333,333
Stock Options Outstanding
Options Granted (in shares)				1,927,121	241,500
Options Cancelled (in shares)				(147,778)	(15,000)
Weighted Average Stock Option Exercise Price
Options Granted (in dollars per share)				$ 1.97	$ 4.32
Options Cancelled (in dollars per share)				$ 2.28	$ 5.09
2014 Plan \| Stock options
Stock Incentive Plans
Number of shares reserved for issuance	333,333
Increase in shares reserve based on outstanding number of shares	162,498
Additional shares authorized (in shares)		1,550,000	550,000
Increase in share reserve based on outstanding number of shares (as a percent)	2.00%
Shares Available for Grant
Shares Authorized (in shares)	333,333

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Taxes
Net loss and comprehensive loss	$ 14,733,780	$ 16,291,550
Deferred:
Federal	(4,387,544)	(4,197,007)
State	(1,249,149)	(587,696)
Total deferred	(5,636,693)	(4,784,703)
Less: valuation allowance	$ 5,636,693	$ 4,784,703
Effective tax rate, differed from the federal statutory rate
Statutory rate (as a percent)	(34.00%)	(34.00%)
State taxes (as a percent)	(5.60%)	(3.60%)
Tax credits (as a percent)	(0.50%)	5.20%
Other (as a percent)	1.80%	1.70%
Valuation allowance (as a percent)	38.30%	30.70%
Effective tax rate (as a percent)	0.00%	0.00%
Non-current deferred tax assets:
Net operating Costs	$ 9,626,610	$ 7,459,489
Tax credits	374,605	261,851
Stock Compensation	297,438	188,602
Fixed Assets and Intangibles	3,700,557	470,577
Other	(93,434)	(75,432)
Gross non-current deferred tax assets	14,092,644	8,455,951
Valuation allowance	(14,092,644)	$ (8,455,951)
Increase in valuation allowance	$ 5,636,693

Organization and Business	12 Months Ended
Organization and Business	Dec. 31, 2016
Organization and Business
Organization and Business	1. Organization and Business Jaguar Animal Health, Inc. ("Jaguar" or the "Company") was incorporated on June 6, 2013 (inception) in Delaware. The Company was a majority-owned subsidiary of Napo Pharmaceuticals, Inc. ("Napo" or the "Former Parent") until the close of the Company's initial public offering on May 18, 2015. The Company was formed to develop and commercialize first-in-class gastrointestinal products for companion and production animals and horses. The Company's first commercial product, Neonorm Calf, was launched in 2014 and Neonorm Foal was launched in the first quarter of 2016. In September of 2016, the Company began selling the Croton lechleri botanical extract (the "botanical extract") to an exclusive distributor for use in pigs in China. The Company's activities are subject to significant risks and uncertainties, including failing to secure additional funding in order to timely compete the development and commercialization of products. The Company operates in one segment and is headquartered in San Francisco, California. On June 11, 2013, Jaguar issued 2,666,666 shares of common stock to Napo in exchange for cash and services. On July 1, 2013, Jaguar entered into an employee leasing and overhead agreement (the "Service Agreement") with Napo, under which Napo agreed to provide the Company with the services of certain Napo employees for research and development and the general administrative functions of the Company. On January 27, 2014, Jaguar executed an intellectual property license agreement with Napo pursuant to which Napo transferred fixed assets and development materials, and licensed intellectual property and technology to Jaguar. On February 28, 2014, the Service Agreement terminated and the associated employees became employees of Jaguar effective March 1, 2014. See Note 9 for additional information regarding the capital contributions and Note 4 for the Service Agreement and license agreement details. Effective July 1, 2016, Napo agreed to reimburse the Company for the use of the Company's employee's time and related expenses, including rent and a fixed overhead amount to cover office supplies and copier use. On October 6, 2016, Jaguar signed a non-binding letter of intent ("LOI") with Napo potentially to merge the two companies. Reverse Stock Split In October 2014, the Board of Directors and stockholders approved a 1-for-1.5 reverse stock split (the "Reverse Split") of the Company's outstanding shares of common stock and increased the number of authorized shares of common stock from 10,000,000 shares to 15,000,000 shares. The Company effected the Reverse Split on October 27, 2014. Under the terms of the Reverse Split, each share of common stock, issued and outstanding as of such effective date, was automatically reclassified and changed into two-thirds of one share of common stock, without any action by the stockholder. Fractional shares were rounded down to the nearest whole share. All share and per share amounts have been restated to reflect the Reverse Split. Initial Public Offering On May 18, 2015, the Company completed an initial public offering ("IPO") of its common stock. In connection with its IPO, the Company issued and sold 2,860,000 shares of common stock at a price to the public of $7.00 per share. As a result of the IPO, the Company received $15.9 million in net proceeds, after deducting underwriting discounts and commissions of $1.2 million and offering expenses of $2.9 million ($3.3 million including non-cash offering expenses) payable by the Company. In connection with the IPO, the Company's outstanding shares of convertible preferred stock were automatically converted into 2,010,596 shares of common stock and the Company's outstanding warrants to purchase convertible preferred stock were all converted to warrants to purchase common stock. Liquidity The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring operating losses since inception and has an accumulated deficit of $40,436,108 as of December 31, 2016. The Company expects to incur substantial losses in future periods. Further, the Company's future operations are dependent on the success of the Company's ongoing development and commercialization efforts. There is no assurance that profitable operations, if ever achieved, could be sustained on a continuing basis. The Company plans to finance its operations and capital funding needs through equity and/or debt financing as well as revenue from future product sales. However, there can be no assurance that additional funding will be available to the Company on acceptable terms on a timely basis, if at all, or that the Company will generate sufficient cash from operations to adequately fund operating needs or ultimately achieve profitability. If the Company is unable to obtain an adequate level of financing needed for the long-term development and commercialization of its products, the Company will need to curtail planned activities and reduce costs. Doing so will likely have an adverse effect on the Company's ability to execute on its business plan. These matters raise substantial doubt about the ability of the Company to continue in existence as a going concern within one year after issuance date of the financial statements. The accompanying financial statements do not include any adjustments that might result from the outcome of these uncertainties. In June 2016, the Company entered into a common stock purchase agreement with a private investor (the "CSPA"), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the investor is committed to purchase up to an aggregate of $15.0 million of the Company's common stock over the approximately 30-month term of the agreement. As of December 31, 2016 the Company sold 2,027,490 shares for net cash proceeds of $2,676,700. Under the CSPA, the Company cannot issue more than the 2,027,490 shares of common stock already issued unless the price per share is $1.32 (the closing price on the date that the CSPA was signed).

Redeemable Convertible Preferred Stock	12 Months Ended
Redeemable Convertible Preferred Stock	Dec. 31, 2016
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock	8. Redeemable Convertible Preferred Stock In February, April and May of 2014, the Company issued 3,015,902 shares of convertible preferred stock in exchange for $6,777,338. The redemption value of the convertible preferred stock was $9.0 million. The differences between the respective redemption values/liquidation preference and carrying values are being accreted over the period from the date of issuance to the earliest possible redemption date, February 2017. The Company has recorded accretion of $263,060 for the year ended December 31, 2015. Costs incurred in connection with the issuance of Series A redeemable convertible preferred stock during the year ended December 31, 2014 were $119,097 which have been recorded as a reduction to the carrying amounts of convertible preferred stock and are being accreted to the carrying value of the applicable preferred stock to the redemption date. The Company has recorded accretion of $83,334 for the year ended December 31, 2015. On May 18, 2015, the Company completed its IPO. In connection with the IPO, all of the Company's 3,015,902 outstanding shares of convertible preferred stock were automatically converted into 2,010,596 shares of common stock. Prior to this conversion event, Convertible Preferred Stock had been classified outside of stockholders' (deficit) in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities.

401(k) Plan	12 Months Ended
401(k) Plan	Dec. 31, 2016
401(k) Plan
401(k) Plan	13. 401(k) Plan The Company sponsors a 401(k) defined contribution plan covering all employees. There were no employer contributions to the plan from plan inception through December 31, 2016.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2016
Subsequent Events
Subsequent Events	14. Subsequent Events The Company completed an evaluation of the impact of subsequent events through February 15, 2017, the date these financial statements were issued. Commercializaton Agreement On January 27, 2017, the Company announced it entered into a licensing, development, co-promotion and commercialization agreement with Elanco US Inc. ("Elanco") to license, develop and commercialize Canalevia, a Company drug product candidate under investigation for treatment of acute and chemotherapy-induced diarrhea in dogs, and other drug product formulations of crofelemer for treatment of gastrointestinal diseases, conditions and symptoms in cats and other companion animals (collectively, the "Licensed Products"). The Elanco Agreement grants Elanco exclusive global rights to Canalevia, a product whose active pharmaceutical ingredient is sustainably isolated and purified from the Croton lechleri tree, for use in companion animals. Pursuant to the Elanco Agreement, Elanco will have exclusive rights globally outside the U.S. and co-exclusive rights with the Company in the U.S. to direct all marketing, advertising, promotion, launch and sales activities related to the Licensed Products. Under the terms of the Elanco Agreement, the Company received a $1.5 million upfront payment and will receive additional payments upon achievement of certain development, regulatory and sales milestones in an aggregate amount of up to $61.0 million payable throughout the term of the Elanco Agreement, as well as product development expense reimbursement, and royalty payments on global sales. The Elanco Agreement specifies that the Company will supply the Licensed Products to Elanco, and that the parties will agree to set a minimum sales requirement that Elanco must meet to maintain exclusivity. The Elanco Agreement also contains provisions regarding payment terms, confidentiality and indemnification, as well as other customary provisions. Elanco will also reimburse the Company for Canalevia-related expenses, including reimbursement for Canalevia-related expenses in Q4 2016, certain development and regulatory expenses related to the Company's planned target animal safety study and the completion of the Company's field study of Canalevia for acute diarrhea in dogs. 2015 Convertible Notes Payable On January 31, 2017, the Company entered into an amendment to extend the due date of the $150,000 convertible note payable from January 31, 2017 to January 1, 2018. In exchange for the extension of the maturity date, on January 31, 2017, the Company's board of directors granted the convertible note holder a warrant to purchase 370,916 shares of the Company's common stock for $0.51 per share. The warrant is exercisable at any time on or before January 31, 2019, the expiration date of the warrant. Merger Agreement On February 8, 2017, the Company announced that it had entered into a binding agreement of terms (the "Agreement") to merge with Napo Pharmaceuticals, Inc., the Company's former parent. The transaction was approved by the unanimous vote of independent and disinterested members of each of Jaguar's and Napo's Board of Directors. Napo will operate as a wholly-owned subsidiary of Jaguar, focused on human health. The binding financial terms of the merger include a 3-to-1 Napo-to-Jaguar value ratio to calculate the relative ownership of the combined entity. As of January 31, 2017, Napo owned approximately 19% of Jaguar's outstanding shares of common stock. The Agreement sets forth the financial terms of the merger and customary conditions to closing, which include but are not limited to completion of due diligence, receipt of a fairness opinion, and stockholder and other approvals. Additionally, the financial terms of the merger and conditions to closing include provisions that (i) Napo's secured convertible debt shall not exceed $10.0 million and its unsecured debt shall not exceed $3.0 million, and (ii) a third party will invest $3.0 million in the Company for approximately four million shares of newly issued common stock of the Company with the investment proceeds loaned to Napo immediately prior to the consummation of the merger. The Agreement also provides that if the merger fails to close for any reason on or prior to July 31, 2017, other than as a result directly or indirectly of (x) lack of stockholder approval by either party or (y) Napo (i) failing to perform in accordance with the terms and conditions of the Agreement or (ii) failing to abide by or breaching the provisions or representations, warranties and covenants of the Agreement or the merger documents, then, on or before the close of business on August 7, 2017, the Company will be required to issue 2,000,000 shares of its restricted common stock to Napo.

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Deferred Financing Costs
Deferred Offering Costs	$ 72,710	$ 143,231
IPO
Deferred Financing Costs
Deferred Offering Costs	$ 72,710
Secondary public offering
Deferred Financing Costs
Deferred Offering Costs		$ 143,231
Equipment \| Minimum
Property and Equipment
Estimated useful lives	3 years
Equipment \| Maximum
Property and Equipment
Estimated useful lives	10 years

Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	14,007,132	8,124,923
Common stock, shares outstanding	14,007,132	8,124,923

Statement of Changes in Common Stock, Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)	12 Months Ended
	Dec. 31, 2016 USD ($)
Stock Transactions, Parenthetical Disclosures
Warrant liability	$ 799,201
Warrants issuance cost	(39,200)
Common Stock \| Private Investment in Public Entities June 2016
Stock Transactions, Parenthetical Disclosures
Offering costs	105,398
Common Stock \| Private Investment in Public Entities November 2016
Stock Transactions, Parenthetical Disclosures
Offering costs	96,833
Warrant liability	$ 700,001

Summary of Significant Accounting Policies - Restricted Cash and Inventories (Details) - USD ($)		12 Months Ended
	Aug. 18, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 22, 2015
Restricted Cash
Maximum borrowing capacity	$ 8.0
Initial loan commitment	6.0
Base minimum cash balance	$ 4,500,000		$ 3,000,000	$ 3,000,000
Repayment of loan from restricted cash		$ 2,500,000
Restricted cash, current		511,293
Inventories
Inventory write-downs		$ 0

Summary of Significant Accounting Policies - Property and Equipment (Details) - Equipment	12 Months Ended
	Dec. 31, 2016
Minimum
Property and Equipment
Property, Plant and Equipment, Useful Life	3 years
Maximum
Property and Equipment
Property, Plant and Equipment, Useful Life	10 years

Summary of Significant Accounting Policies - Revenue Recognition (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue Recognition
Revenues	$ 141,523	$ 258,381

Fair Value Measurements - Fair Value of Liabilities Measured on a Recurring Basis (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair value of liabilities measured on a recurring basis
Warrant liability	$ 799,201	$ 0
Recurring
Fair value of liabilities measured on a recurring basis
Warrant liability	799,201
Recurring \| Level 3
Fair value of liabilities measured on a recurring basis
Warrant liability	$ 799,201		$ 601,889

Fair Value Measurements - Estimated Fair Value of Warrant Liability (Details) - USD ($)			1 Months Ended	12 Months Ended
	Dec. 31, 2016	Nov. 08, 2016	Nov. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Change in the estimated fair value of the warrant liability
Beginning value of warrant liability				$ 0
Issuance of Common Warrants					$ 47,479
Change in Fair Value of Level 3 Liability				43,200	501,617
Conversion into Additional Paid-in Capital					1,202,521
Ending value of warrant liability	$ 799,201			$ 799,201	0
Fair Value Assumptions and Methodology for Assets and Liabilities
Stock price	$ 0.716	$ 0.91	$ 0.69	$ 0.716
Exercise price	$ 0.75	$ 0.01	$ 0.75	$ 0.75
Term	5 years 4 months 28 days	5 years 8 months 19 days	5 years 6 months
Volatility (as a percent)	73.62%	70.35%	71.92%
Dividend yield (as a percent)	0.00%	0.00%	0.00%
Risk-free interest rate (as a percent)	2.00%	1.45%	1.87%
Recurring
Change in the estimated fair value of the warrant liability
Ending value of warrant liability	$ 799,201			$ 799,201
Level 3 \| Recurring
Change in the estimated fair value of the warrant liability
Beginning value of warrant liability					601,889
Issuance of Common Warrants				756,001	47,479
Change in Fair Value of Level 3 Liability				43,200	501,617
Conversion into Additional Paid-in Capital					$ (1,150,985)
Ending value of warrant liability	$ 799,201			$ 799,201

Related Party Transactions (Details) - USD ($)	3 Months Ended	6 Months Ended	12 Months Ended
Related Party Transactions (Details) - USD ($)	May 31, 2014	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Napo
Related Party Transactions
Due from former parent		$ 299,819	$ 299,819	$ 6,008
Royalty payable to former parent		(171)	(171)	(2,809)
Net receivable from former parent		299,648	299,648	3,199
License fee payable to Napo				(425,000)
Payments for consulting, travel and computer equipment on behalf of related party			22,290
Net payments on behalf of related party				6,008
Legal services paid by company				15,000
Consulting services paid				8,992
Related party purchases			37,355
Napo \| General and administrative expense
Related Party Transactions
Rent related to the office space					$ 33,897
Napo \| Prepaid expenses
Related Party Transactions
Remaining unused materials from the related party purchases			897
Napo \| Crofelemer API
Related Party Transactions
Related party purchases			174,299
Napo \| Crude plant latex
Related Party Transactions
Related party purchases			66,358
Napo \| Service Agreement
Related Party Transactions
Remittance from related party			350,000
Outstanding receivables		277,529	$ 277,529
Napo
Related Party Transactions
Rent related to the office space	$ 33,897			$ 69,580	$ 80,816
Napo \| Service Agreement
Related Party Transactions
Amount of share employee services		$ 627,529

Balance Sheet Components - Accrued Expenses (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Accrued compensation and related:
Accrued vacation	$ 223,769	$ 187,734
Accrued payroll	2,692	80,692
Accrued payroll tax	20,140	43,702
Total of accrued compensation and related	246,601	312,128
Accrued interest	123,982	127,149
Accrued contract manufacturing costs		110,141
Accrued clinical	36,725	166,750
Accrued other	175,214	82,266
Total	$ 582,522	$ 798,434

Commitments and Contingencies - Operating Leases (Details) - USD ($)		3 Months Ended	6 Months Ended	12 Months Ended
	Jul. 01, 2015	May 31, 2014	Jun. 30, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Commitments and Contingencies
Cash deposits under non-cancelable sub-lease agreement	$ 122,163.00
Security deposit under non-cancelable sub-lease agreement	29,539.00
Future minimum lease payments under non-cancellable operating leases
2017				$ 363,486
2018				245,327
Total minimum lease payments				608,813
Other assets
Commitments and Contingencies
Prepayment of last three months lease payments	$ 92,623.00
Napo
Commitments and Contingencies
Rent related to the office space		$ 33,897			$ 69,580	$ 80,816
General and administrative expense
Commitments and Contingencies
Rent expense under non-cancelable operating lease			$ 180,557	$ 361,114

Debt and Warrants - Warrants (Details) - USD ($)					1 Months Ended	12 Months Ended
Debt and Warrants - Warrants (Details) - USD ($)	Dec. 31, 2016	Nov. 29, 2016	Nov. 22, 2016	Nov. 08, 2016	Nov. 30, 2016	Dec. 31, 2016	Dec. 31, 2015
Debt and Warrants
Share issue price (in dollars per share)	$ 0.716			$ 0.91	$ 0.69	$ 0.716
Amount of shares issued							$ 15,512,260
Warrant Activity
Number of warrants issued to purchase shares of common stock (in shares)	67,655					67,655	26,785
Strike price (in dollars per share)				$ 0.01
Expected life	5 years 4 months 28 days			5 years 8 months 19 days	5 years 6 months
Volatility (as a percent)	73.62%			70.35%	71.92%
Closing price (in dollars per share)		$ 0.69
Risk-free interest rate (as a percent)	2.00%			1.45%	1.87%
Revaluation of warrant liability						$ 43,200	$ 501,617
Warrants outstanding at beginning of period						748,872	494,267
Issuances						5,253,337	254,605
Cancellations						(33,333)
Warrants outstanding at end of period	5,968,876					5,968,876	748,872
Series A warrants and placement agent warrants
Warrant Activity
Strike price (in dollars per share)	$ 0.75					$ 0.75
Expected life	5 years 4 months 28 days		5 years 6 months
Volatility (as a percent)	73.62%		71.92%
Risk-free interest rate (as a percent)	2.00%		1.87%
Warrant liability	$ 799,201					$ 799,201
Revaluation of warrant liability	$ 43,200
Series A Warrants
Warrant Activity
Number of warrants issued to purchase shares of common stock (in shares)			1,666,668
Strike price (in dollars per share)			$ 0.75
Warrant liability		$ 756,001	$ 756,001
Placement agent Warrants
Warrant Activity
Number of warrants issued to purchase shares of common stock (in shares)			133,333
Series B warrants
Warrant Activity
Number of warrants issued to purchase shares of common stock (in shares)			1,666,668
Strike price (in dollars per share)			$ 0.90
Expected life			1 year
Volatility (as a percent)			116.65%
Risk-free interest rate (as a percent)			0.78%
Series C warrants
Warrant Activity
Number of warrants issued to purchase shares of common stock (in shares)			1,666,668
Strike price (in dollars per share)			$ 1.00
Expected life			1 year 6 months
Volatility (as a percent)			116.92%
Risk-free interest rate (as a percent)			0.94%
2016 Private Placement
Debt and Warrants
Shares issued (in shares)			1,666,668
Share issue price (in dollars per share)			$ 0.60
Amount of shares issued			$ 1,000,000

Redeemable Convertible Preferred Stock (Details) - USD ($)		12 Months Ended
	May 18, 2015	Dec. 31, 2015	Dec. 31, 2014	May 31, 2014	Apr. 30, 2014	Feb. 28, 2014
Redeemable Convertible Preferred Stock
Preferred shares issued				3,015,902	3,015,902	3,015,902
Liquidation preference				$ 6,777,338
Redemption value				$ 9,000,000
Accretion of deemed dividend		$ 263,060
Issuance costs incurred		417,775
Common Stock \| IPO
Redeemable Convertible Preferred Stock
Issuance of common stock upon conversion (in shares)	2,010,596
Series A redeemable convertible preferred stock
Redeemable Convertible Preferred Stock
Issuance costs incurred			$ 119,097
Accretion of issuance costs		$ 83,334
Preferred shares outstanding	3,015,902

Stock Incentive Plans - Restricted Units (Details) - shares	Jul. 01, 2017	Jan. 01, 2016
Stock Incentive Plans
Issuance of common stock in exchange for vested restricted stock units (in shares)		17,546
Restricted stock units
Stock Incentive Plans
RSUs, vested and released, gross (in shares)		27,768
RSU shares used to pay withholding taxes (in shares)		10,172
2013 Plan \| Restricted stock units
Stock Incentive Plans
Vesting (as a percent)		50.00%
2013 Plan \| Restricted stock units \| Forecast
Stock Incentive Plans
Vesting (as a percent)	50.00%

Net Loss Per Share Attributable to Common Stockholders- Calculation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Calculation of basic and diluted net loss per common share
Net loss attributable to common stockholders	$ (14,733,780)	$ (16,637,924)
Shares used to compute net loss per common share, basic and diluted (in shares)	10,951,178	6,153,139
Net loss per share attributable to common shareholders, basic and diluted	$ (1.35)	$ (2.70)

Net Loss Per Share Attributable to Common Stockholders- Excluded From Calculation (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	8,560,885	1,723,914
Options
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	2,571,220	919,506
Warrants to purchase common stock
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	5,968,876	748,872
Restricted stock units
Outstanding common stock equivalents have been excluded from diluted net loss per common share
Outstanding common stock equivalents have been excluded from diluted net loss per common share (in shares)	20,789	55,536

Income Taxes - Net Operating Loss Carryover (Details)	Dec. 31, 2016 USD ($)
Federal
Net operating loss carryovers
Net operating loss carryovers	$ 24,543,368
California
Net operating loss carryovers
Net operating loss carryovers	$ 17,103,817

Income Taxes - Tax Credit Carryover (Details) - Research	Dec. 31, 2016 USD ($)
Federal
Tax credit carryovers
Tax credit carryovers	$ 279,793
California
Tax credit carryovers
Tax credit carryovers	$ 285,554

Income Taxes - Reconciliation (Details) - USD ($)	12 Months Ended
Income Taxes - Reconciliation (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Reconciliation of the beginning and ending amounts of unrecognized tax benefits
Gross unrecognized tax benefit - beginning balance	$ 78,930	$ 31,006
Increases related to tax positions from prior years		5,920
Increases related to tax positions taken during the current year	34,143	42,004
Gross unrecognized tax benefit - ending balance	113,073	78,930
Liabilities from unrecognized tax benefits	$ 0	$ 0
Federal
Reconciliation of the beginning and ending amounts of unrecognized tax benefits
Statute of limitations regarding tax returns	3 years
California
Reconciliation of the beginning and ending amounts of unrecognized tax benefits
Statute of limitations regarding tax returns	4 years

401(k) Plan (Details)	12 Months Ended
401(k) Plan (Details)	Dec. 31, 2016 USD ($)
401(k) Plan
Employer contributions to the plan	$ 0

Subsequent Events (Details)					12 Months Ended
Subsequent Events (Details)	Feb. 08, 2017 shares	Jan. 31, 2017 USD ($) shares	Jan. 27, 2017 USD ($)	Nov. 22, 2016 USD ($)	Dec. 31, 2015 USD ($) shares	Dec. 31, 2016 $ / shares shares	Nov. 30, 2016 $ / shares	Nov. 08, 2016 $ / shares shares	Jan. 31, 2016 $ / shares shares	Jun. 02, 2014 USD ($)
Subsequent Event
Notes payable										$ 300,000
Number of warrants issued to purchase shares of common stock (in shares) \| shares					26,785	67,655
Strike price (in dollars per share) \| $ / shares						$ 0.716	$ 0.69	$ 0.91
Amount of shares issued					$ 15,512,260
Common Stock
Subsequent Event
Amount of shares issued				$ 106,000	$ 286
Shares issued (in shares) \| shares					2,860,000
Convertible promissory note issued to Serious Change II LP
Subsequent Event
Number of warrants issued to purchase shares of common stock (in shares) \| shares								120,000	370,916
Strike price (in dollars per share) \| $ / shares									$ 0.51
Subsequent events \| Restricted common stock
Subsequent Event
Stock issuable by the entity, if failing to abide of binding agreement (in shares) \| shares	2,000,000
Subsequent events \| Napo
Subsequent Event
Merger stock conversion ratio	33.33
Percentage of voting interests (as a percent)	19.00%
Maximum amount of unsecured debt		$ 3,000,000
Subsequent events \| Napo \| Common Stock
Subsequent Event
Amount of shares issued		$ 3,000,000
Shares issued (in shares) \| shares		4,000,000
Subsequent events \| Convertible promissory note issued to Serious Change II LP
Subsequent Event
Notes payable		$ 150,000
Subsequent events \| Convertible debt \| Napo
Subsequent Event
Maximum amount of secured convertible debt		$ 10,000,000
Elanco \| Subsequent events
Subsequent Event
Upfront payment received			$ 1,500,000
Additional payment receivable upon achievement			$ 61,000,000